In|O this|O experimental|O study|O we|O used|O 30|O Sprague|O -|O Dawley|O rats|O ,|O 27|O of|O which|O had|O gentamicin|O instilled|O into|O the|O middle|O ear|O .|O
A|O total|O of|O 167|O courses|O at|O doses|O of|O 15|O to|O 70|O mg|O /|O m2|O were|O evaluable|O .|O
Drug|O -|O induced|O hepatotoxicity|B-Disease ,|O although|O common|O ,|O has|O been|O reported|O only|O infrequently|O with|O sulfonylureas|O .|O
AKBR|O and|O biological|O hepatic|O function|O tests|O showed|O no|O change|O throughout|O the|O time|O course|O in|O groups|O A|O and|O B|O .|O
Mean|O serum|O creatinine|O level|O before|O conversion|O was|O 2|O .|O 21|O mg|O /|O dL|O and|O thereafter|O ,|O 4|O .|O 93|O mg|O /|O dL|O (|O P|O =|O .|O 02|O )|O .|O
Migraine|B-Disease (|O 20|O %|O )|O was|O not|O an|O uncommon|O cause|O of|O cranial|B-Disease neuropathy|I-Disease although|O malignancies|B-Disease arising|O from|O the|O reticuloendothelial|O system|O or|O related|O structures|O of|O the|O head|O and|O neck|O were|O more|O frequent|O (|O 26|O %|O )|O .|O
Sulfasalazine|O -|O induced|O lupus|B-Disease erythematosus|I-Disease .|O
One|O month|O previously|O ,|O she|O had|O taken|O a|O single|O high|O dose|O of|O disulfiram|O (|O 130|O tablets|O of|O ALCOHOL|O STOP|O TAB|O ,|O Shin|O -|O Poong|O Pharm|O .|O Co|O .|O ,|O Ansan|O ,|O Korea|O )|O in|O a|O suicide|O attempt|O .|O
The|O patient|O was|O taking|O 80|O mg|O simvastatin|O at|O bedtime|O (|O initiated|O 27|O days|O earlier|O )|O ;|O amiodarone|O at|O a|O dose|O of|O 400|O mg|O daily|O for|O 7|O days|O ,|O then|O 200|O mg|O daily|O (|O initiated|O 19|O days|O earlier|O )|O ;|O and|O 400|O mg|O atazanavir|O daily|O (|O initiated|O at|O least|O 2|O years|O previously|O )|O .|O
The|O duration|O of|O action|O may|O be|O prolonged|O in|O patients|O with|O genetic|O variants|O of|O the|O butyrylcholinesterase|O enzyme|O (|O BChE|O )|O ,|O the|O most|O common|O being|O the|O K|O -|O and|O the|O A|O -|O variants|O .|O
L|O -|O NAME|O reduced|O gentamicin|O -|O induced|O hearing|B-Disease loss|I-Disease in|O the|O high|O -|O frequency|O range|O ,|O but|O gave|O no|O protection|O in|O the|O middle|O or|O low|O frequencies|O .|O
Diseases|B-Disease of|I-Disease peripheral|I-Disease nerves|I-Disease as|O seen|O in|O the|O Nigerian|O African|O .|O
Twenty|O -|O eight|O percent|O of|O patients|O showed|O increased|O proteinuria|B-Disease to|O the|O nephrotic|B-Disease range|O .|O
Fifty|O -|O eight|O patients|O (|O 78|O %|O )|O had|O normal|O renal|O tests|O ,|O whereas|O 16|O patients|O (|O 22|O %|O )|O had|O renal|B-Disease abnormalities|I-Disease .|O
Proximal|O muscle|B-Disease weakness|I-Disease has|O developed|O during|O her|O follow|O -|O up|O .|O
Two|O subsets|O of|O patients|O were|O identified|O from|O this|O latter|O group|O :|O the|O first|O included|O four|O patients|O (|O 5|O %|O of|O the|O total|O population|O )|O who|O developed|O major|O toxicity|B-Disease resulting|O in|O Fanconi|B-Disease '|I-Disease s|I-Disease syndrome|I-Disease (|O TDFS|B-Disease )|O ;|O and|O the|O second|O group|O included|O five|O patients|O with|O elevated|O beta|O 2|O microglobulinuria|O and|O low|O phosphate|O reabsorption|O .|O
Based|O on|O the|O finding|O that|O VPU|O and|O VPA|O could|O protect|O the|O animals|O against|O pilocarpine|O -|O induced|O seizure|B-Disease it|O is|O suggested|O that|O the|O reduction|O of|O inhibitory|O amino|O acid|O neurotransmitters|O was|O comparatively|O minor|O and|O offset|O by|O a|O pronounced|O reduction|O of|O glutamate|O and|O aspartate|O .|O
Acute|O vocal|B-Disease fold|I-Disease palsy|I-Disease after|O acute|O disulfiram|O intoxication|O .|O
METHODS|O :|O 3|O -|O methyladenine|O (|O 3MA|O )|O ,|O a|O specific|O inhibitor|O on|O autophagy|O was|O used|O in|O a|O heart|B-Disease failure|I-Disease model|O of|O rats|O induced|O by|O adriamycin|O .|O
This|O concerns|O 2|O male|O patients|O who|O experienced|O incontinence|B-Disease while|O taking|O venlafaxine|O .|O
The|O high|O image|O quality|O suggests|O that|O high|O contrast|O images|O can|O be|O obtained|O in|O humans|O and|O the|O 96|O h|O stability|O makes|O it|O an|O ideal|O agent|O to|O detect|O ,|O in|O patients|O ,|O early|O cardiac|B-Disease infarction|I-Disease .|O
Manifestations|O regressed|O spontaneously|O under|O surveillance|O in|O the|O hospital|O .|O
Haemolytic|B-Disease -|I-Disease uraemic|I-Disease syndrome|I-Disease after|O treatment|O with|O metronidazole|O .|O
Paracetamol|O -|O associated|O coma|B-Disease ,|O metabolic|B-Disease acidosis|Mention text="metabolic acidosis" start=5 end=7 type=Disease prob=null&Mention text="acidosis" start=6 end=7 type=Disease prob=null ,|O renal|B-Disease and|I-Disease hepatic|I-Disease failure|I-Disease .|O
In|O less|O than|O 1|O hour|O after|O the|O ingestion|O of|O alcohol|O ,|O he|O developed|O malaise|O with|O flushing|B-Disease of|I-Disease the|I-Disease face|I-Disease ,|O tachycardia|B-Disease ,|O and|O dyspnea|B-Disease .|O
In|O 40|O %|O it|O increased|O by|O more|O than|O 100|O %|O .|O
To|O clarify|O the|O effects|O of|O bromocriptine|O on|O prolactinoma|B-Disease cells|O in|O vivo|O ,|O immunohistochemical|O ,|O ultrastructural|O and|O morphometrical|O analyses|O were|O applied|O to|O estrogen|O -|O induced|O rat|O prolactinoma|B-Disease cells|O 1|O h|O and|O 6|O h|O after|O injection|O of|O bromocriptine|O (|O 3|O mg|O /|O kg|O of|O body|O weight|O )|O .|O
Improved|O outcomes|O among|O patients|O with|O head|B-Disease and|I-Disease neck|I-Disease carcinomas|I-Disease require|O investigations|O of|O new|O drugs|O for|O induction|O therapy|O .|O
Associated|O corticosteroid|O therapy|O and|O twin|O gestations|O appear|O to|O be|O predisposing|O factors|O .|O
Glyburide|O can|O produce|O an|O acute|B-Disease hepatitis|I-Disease -|I-Disease like|I-Disease illness|I-Disease in|O some|O persons|O .|O
Physicians|O who|O use|O sulfasalazine|O to|O treat|O patients|O with|O inflammatory|B-Disease bowel|I-Disease disease|I-Disease should|O be|O aware|O of|O the|O signs|O of|O sulfasalazine|O -|O induced|O lupus|B-Disease syndrome|I-Disease .|O
There|O is|O a|O male|O preponderance|O and|O the|O peak|O incidence|O is|O in|O the|O fourth|O decade|O .|O
In|O the|O '|O conscious|O catheterized|O rat|O '|O model|O ,|O the|O glomerular|O filtration|O rate|O (|O GFR|O )|O was|O measured|O as|O the|O clearance|O of|O Cr|O (|O EDTA|O )|O .|O
The|O maximal|O NGF|O contents|O obtained|O by|O PG|O -|O 9|O were|O 17|O .|O 6|O -|O fold|O of|O the|O control|O value|O .|O
The|O most|O common|O primary|O tumor|B-Disease site|O was|O the|O head|O and|O neck|O .|O
Acute|O effects|O of|O N|O -|O (|O 2|O -|O propylpentanoyl|O )|O urea|O on|O hippocampal|O amino|O acid|O neurotransmitters|O in|O pilocarpine|O -|O induced|O seizure|B-Disease in|O rats|O .|O
The|O study|O investigates|O if|O alpha|O -|O lipoic|O acid|O is|O neuroprotective|O against|O chemotherapy|O induced|O neurotoxicity|B-Disease ,|O if|O mitochondrial|B-Disease damage|I-Disease plays|O a|O critical|O role|O in|O toxic|B-Disease neurodegenerative|I-Disease cascade|I-Disease ,|O and|O if|O neuroprotective|O effects|O of|O alpha|O -|O lipoic|O acid|O depend|O on|O mitochondria|O protection|O .|O
The|O serum|O magnesium|O concentration|O was|O 3|O .|O 0|O mEq|O /|O L|O ,|O which|O is|O usually|O well|O tolerated|O .|O
A|O chi|O -|O square|O test|O was|O used|O to|O assess|O the|O statistical|O significance|O of|O results|O .|O
The|O otoprotectant|O L|O -|O NAME|O was|O administered|O topically|O to|O 12|O /|O 27|O animals|O .|O
Clinical|O and|O histopathologic|O examination|O of|O renal|O allografts|O treated|O with|O tacrolimus|O (|O FK506|O )|O for|O at|O least|O one|O year|O .|O
The|O morphological|O changes|O presented|O a|O similar|O pattern|O .|O
This|O case|O illustrates|O the|O need|O for|O close|O vigilance|O in|O adverse|B-Disease drug|I-Disease reactions|I-Disease ,|O particularly|O in|O the|O elderly|O .|O
One|O h|O after|O treatment|O ,|O serum|O prolactin|O levels|O decreased|O markedly|O .|O
Our|O results|O demonstrate|O that|O both|O cisplatin|O and|O paclitaxel|O cause|O early|O mitochondrial|B-Disease impairment|I-Disease with|O loss|O of|O membrane|O potential|O and|O induction|O of|O autophagic|O vacuoles|O in|O neurons|O .|O
The|O dose|O of|O gabapentin|O was|O 1|O ,|O 800|O mg|O per|O os|O ,|O in|O a|O single|O administration|O .|O
Haemodilution|B-Disease in|O groups|O B|O and|O C|O was|O produced|O by|O withdrawing|O approximately|O 1000|O mL|O of|O blood|O and|O replacing|O it|O with|O the|O same|O amount|O of|O dextran|O solution|O ,|O and|O final|O haematocrit|O values|O were|O 21|O or|O 22|O %|O .|O
They|O suggest|O that|O ,|O in|O normal|O conscious|O rats|O ,|O the|O central|O tachycardia|B-Disease of|O bromocriptine|O appears|O to|O predominate|O and|O to|O mask|O the|O bradycardia|B-Disease of|O this|O agonist|O at|O peripheral|O dopamine|O D2|O receptors|O .|O
Many|O of|O these|O patients|O are|O taking|O pentoxifylline|O (|O Trental|O )|O ,|O a|O methylxanthine|O derivative|O which|O may|O improve|O intermittent|B-Disease claudication|I-Disease .|O
The|O aim|O of|O this|O study|O was|O to|O assess|O the|O effects|O of|O gabapentin|O ,|O a|O drug|O effective|O in|O neuropathic|B-Disease pain|I-Disease patients|O ,|O on|O brain|O processing|O of|O nociceptive|O information|O in|O normal|O and|O central|O sensitization|O states|O .|O
In|O 28|O %|O of|O patients|O proteinuria|B-Disease remained|O unchanged|O ,|O whereas|O it|O increased|O in|O 68|O %|O of|O patients|O .|O
The|O observed|O drug|O -|O induced|O effects|O were|O not|O due|O to|O changes|O in|O the|O baseline|O fMRI|O signal|O .|O
These|O are|O nephrotoxic|B-Disease ,|O but|O SRL|O seems|O to|O act|O differently|O displaying|O only|O minor|O nephrotoxic|B-Disease effects|O ,|O although|O this|O question|O is|O still|O open|O .|O
The|O girl|O died|O seven|O days|O ,|O the|O man|O four|O weeks|O after|O intrathecal|O injection|O of|O vincristine|O .|O
The|O stereotypies|O induced|O by|O d|O -|O amphetamine|O or|O apomorphine|O are|O not|O potentiated|O by|O TRI|O .|O
Whether|O pentoxifylline|O inhibits|O dipyridamole|O -|O induced|O coronary|O hyperemia|B-Disease like|O other|O methylxanthines|O such|O as|O theophylline|O and|O should|O be|O stopped|O prior|O to|O dipyridamole|O -|O thallium|O -|O 201|O imaging|O is|O unknown|O .|O
Renal|B-Disease Fanconi|I-Disease syndrome|I-Disease and|O myopathy|B-Disease after|O liver|O transplantation|O :|O drug|O -|O related|O mitochondrial|B-Disease cytopathy|I-Disease ?|O
Some|O other|O mechanism|O than|O those|O being|O reported|O herein|O should|O be|O further|O investigated|O .|O
B6|O mice|O were|O resistant|O to|O seizures|B-Disease and|O slower|O to|O reach|O stages|O compared|O to|O A|O /|O J|O mice|O .|O
Advances|O in|O the|O field|O of|O transplantation|O provide|O a|O better|O quality|O of|O life|O and|O allow|O more|O favorable|O conditions|O for|O growth|O and|O development|O in|O children|O .|O
Their|O ototoxicity|B-Disease is|O a|O serious|O health|O problem|O and|O ,|O as|O their|O ototoxic|B-Disease mechanism|O involves|O the|O production|O of|O NO|O ,|O we|O need|O to|O assess|O the|O use|O of|O NO|O inhibitors|O for|O the|O prevention|O of|O aminoglycoside|O -|O induced|O sensorineural|B-Disease hearing|I-Disease loss|I-Disease .|O
These|O findings|O suggest|O that|O alpha|O -|O lipoic|O acid|O might|O reduce|O the|O risk|O of|O developing|O peripheral|B-Disease nerve|I-Disease toxicity|I-Disease in|O patients|O undergoing|O chemotherapy|O and|O encourage|O further|O confirmatory|O clinical|O trials|O .|O
At|O 6|O h|O after|O injection|O ,|O serum|O prolactin|O levels|O were|O still|O considerably|O lower|O than|O in|O controls|O .|O
In|O each|O group|O ,|O SNP|O infusion|O resulted|O in|O an|O initial|O decrease|O in|O blood|O pressure|O from|O 86|O torr|O and|O 83|O torr|O ,|O respectively|O ,|O to|O 48|O torr|O .|O
Less|O frequent|O toxic|O effects|O included|O thrombocytopenia|B-Disease ,|O anemia|B-Disease ,|O nausea|B-Disease ,|O mild|O alopecia|B-Disease ,|O phlebitis|B-Disease ,|O and|O mucositis|B-Disease .|O
A|O 35|O -|O year|O -|O old|O woman|O whose|O cervix|O uteri|O was|O inadvertently|O injected|O with|O 8|O mg|O of|O epinephrine|O developed|O myocardial|B-Disease stunning|I-Disease that|O was|O characterized|O by|O severe|O hemodynamic|O compromise|O ,|O profound|O ,|O albeit|O transient|O ,|O left|B-Disease ventricular|I-Disease systolic|I-Disease and|I-Disease diastolic|I-Disease dysfunction|I-Disease ,|O and|O only|O modestly|O elevated|O biochemical|O markers|O of|O myocardial|B-Disease necrosis|I-Disease .|O
The|O purpose|O of|O this|O report|O is|O to|O describe|O two|O cases|O of|O a|O disulfiram|O -|O like|O syndrome|O following|O occupational|O exposure|O to|O hydrogen|O cyanamide|O .|O
Preliminary|O results|O of|O an|O Eastern|O Cooperative|O Oncology|O Group|O study|O of|O single|O -|O agent|O paclitaxel|O (|O Taxol|O ;|O Bristol|O -|O Myers|O Squibb|O Company|O ,|O Princeton|O ,|O NJ|O )|O reported|O a|O 37|O %|O response|O rate|O in|O patients|O with|O head|B-Disease and|I-Disease neck|I-Disease cancer|I-Disease ,|O and|O the|O paclitaxel|O /|O cisplatin|O combination|O has|O been|O used|O successfully|O and|O has|O significantly|O improved|O median|O response|O duration|O in|O ovarian|B-Disease cancer|I-Disease patients|O .|O
Nine|O days|O later|O the|O patient|O '|O s|O creatine|O kinase|O had|O dropped|O to|O 1695|O U|O /|O L|O and|O creatinine|O was|O 3|O .|O 3|O mg|O /|O dL|O .|O
Iatrogenically|O induced|O intractable|O atrioventricular|B-Disease reentrant|I-Disease tachycardia|I-Disease after|O verapamil|O and|O catheter|O ablation|O in|O a|O patient|O with|O Wolff|B-Disease -|I-Disease Parkinson|I-Disease -|I-Disease White|I-Disease syndrome|I-Disease and|O idiopathic|B-Disease dilated|I-Disease cardiomyopathy|I-Disease .|O
Severe|O toxicity|B-Disease was|O correlated|O with|O the|O higher|O cumulative|O dose|O of|O 60|O g|O /|O m2|O of|O ifosfamide|O ,|O a|O younger|O age|O (|O less|O than|O 2|O 1|O /|O 2|O years|O old|O )|O ,|O and|O a|O predominance|O of|O vesicoprostatic|O tumor|B-Disease involvement|O .|O
Although|O most|O cases|O of|O antibiotic|O induced|O acute|O interstitial|B-Disease nephritis|Mention text="interstitial nephritis" start=7 end=9 type=Disease prob=null&Mention text="nephritis" start=8 end=9 type=Disease prob=null are|O benign|O and|O self|O -|O limited|O ,|O some|O patients|O are|O at|O risk|O for|O permanent|O renal|B-Disease injury|I-Disease .|O
Furthermore|O ,|O adriamycin|O induced|O the|O formation|O of|O autophagic|O vacuoles|O ,|O and|O 3MA|O strongly|O downregulated|O the|O expression|O of|O beclin|O 1|O in|O adriamycin|O -|O induced|O failing|O heart|O and|O inhibited|O the|O formation|O of|O autophagic|O vacuoles|O .|O
An|O unusual|O toxic|O reaction|O to|O axillary|O block|O by|O mepivacaine|O with|O adrenaline|O .|O
Sensori|B-Disease -|I-Disease motor|I-Disease neuropathy|I-Disease was|O the|O commonest|O presentation|O (|O 50|O %|O )|O .|O
The|O animal|O model|O used|O to|O produce|O infarction|B-Disease implies|O artery|O ligation|O but|O chemical|O induction|O can|O be|O easily|O obtained|O with|O isoproterenol|O .|O
A|O patient|O with|O cryptogenic|O cirrhosis|B-Disease and|O disseminated|O sporotrichosis|B-Disease developed|O acute|B-Disease renal|I-Disease failure|I-Disease immediately|O following|O the|O administration|O of|O amphotericin|O B|O on|O four|O separate|O occasions|O .|O
Associated|O factors|O were|O co|O -|O treatment|O with|O other|O centrally|O antimuscarinic|O agents|O ,|O poor|O clinical|O outcome|O ,|O older|O age|O ,|O and|O longer|O hospitalization|O (|O by|O 17|O .|O 5|O days|O ,|O increasing|O cost|O )|O ;|O sex|O ,|O diagnosis|O or|O medical|O co|O -|O morbidity|O ,|O and|O daily|O clozapine|O dose|O ,|O which|O fell|O with|O age|O ,|O were|O unrelated|O .|O
We|O found|O that|O (|O i|O )|O gabapentin|O reduced|O the|O activations|O in|O the|O bilateral|O operculoinsular|O cortex|O ,|O independently|O of|O the|O presence|O of|O central|O sensitization|O ;|O (|O ii|O )|O gabapentin|O reduced|O the|O activation|O in|O the|O brainstem|O ,|O only|O during|O central|O sensitization|O ;|O (|O iii|O )|O gabapentin|O suppressed|O stimulus|O -|O induced|O deactivations|O ,|O only|O during|O central|O sensitization|O ;|O this|O effect|O was|O more|O robust|O than|O the|O effect|O on|O brain|O activation|O .|O
METHODS|O :|O Twenty|O -|O six|O renal|O allograft|O biopsy|O specimens|O from|O 1|O 9|O renal|O transplant|O patients|O who|O underwent|O transplantations|O between|O 1991|O and|O 1993|O were|O evaluated|O .|O
In|O 2|O of|O the|O 3|O cases|O the|O patients|O were|O also|O taking|O lithium|O carbonate|O and|O beta|O -|O blockers|O ,|O both|O of|O which|O could|O have|O contributed|O to|O the|O incontinence|B-Disease .|O
The|O duration|O of|O apnea|B-Disease was|O 5|O -|O 15|O min|O compared|O with|O 3|O -|O 5|O .|O 3|O min|O from|O the|O literature|O .|O
PG|O -|O 9|O was|O also|O able|O to|O increase|O the|O amount|O of|O NGF|O secreted|O in|O vitro|O by|O astrocytes|O in|O a|O dose|O -|O dependent|O manner|O .|O
Circumstances|O leading|O to|O this|O event|O and|O the|O mechanisms|O enabling|O a|O neuromuscular|B-Disease blockade|I-Disease to|O occur|O ,|O following|O the|O administration|O of|O a|O small|O dose|O of|O relaxant|O ,|O are|O discussed|O .|O
In|O the|O same|O experimental|O conditions|O ,|O PG|O -|O 9|O (|O 5|O -|O 20|O microg|O per|O mouse|O ,|O i|O .|O c|O .|O v|O .|O )|O was|O also|O able|O to|O prevent|O antimuscarine|O -|O induced|O amnesia|B-Disease ,|O demonstrating|O a|O central|O localization|O of|O the|O activity|O .|O
This|O study|O suggests|O that|O administration|O of|O low|O doses|O of|O beta|O -|O blockers|O may|O improve|O levodopa|O -|O induced|O ballistic|O and|O choreic|O dyskinesia|B-Disease in|O PD|B-Disease .|O
Control|O rats|O received|O halothane|O anesthesia|O (|O 1|O MAC|O )|O for|O one|O hour|O ,|O followed|O by|O SNP|O infusion|O ,|O 40|O microgram|O /|O kg|O /|O min|O ,|O for|O 30|O min|O ,|O followed|O by|O a|O 30|O -|O min|O recovery|O period|O .|O
In|O the|O present|O experiment|O calcitonin|O decreased|O locomotor|O activity|O when|O locally|O injected|O into|O the|O same|O sites|O where|O it|O decreases|O food|O intake|O .|O
Animal|O studies|O suggest|O that|O incontinence|B-Disease secondary|O to|O serotonergic|O antidepressants|O could|O be|O mediated|O by|O the|O 5HT4|O receptors|O found|O on|O the|O bladder|O .|O
In|O patients|O requiring|O the|O concurrent|O use|O of|O statins|O and|O CYP3A4|O inhibitors|O ,|O pravastatin|O ,|O fluvastatin|O ,|O and|O rosuvastatin|O carry|O the|O lowest|O risk|O of|O drug|O interactions|O ;|O atorvastatin|O carries|O moderate|O risk|O ,|O whereas|O simvastatin|O and|O lovastatin|O have|O the|O highest|O risk|O and|O should|O be|O avoided|O in|O patients|O taking|O concomitant|O CYP3A4|O inhibitors|O .|O
Severe|O reversible|O left|B-Disease ventricular|I-Disease systolic|I-Disease and|I-Disease diastolic|I-Disease dysfunction|I-Disease due|O to|O accidental|O iatrogenic|O epinephrine|O overdose|B-Disease .|O
PURPOSE|O :|O To|O assess|O the|O incidence|O of|O postoperative|O emetic|O side|O effects|O after|O the|O administration|O of|O methylprednisolone|O and|O gentamicin|O into|O the|O posterior|O sub|O -|O Tenon|O '|O s|O space|O at|O the|O end|O of|O routine|O cataract|B-Disease surgery|O .|O
In|O addition|O ,|O we|O analyzed|O the|O expression|O of|O autophagy|O associated|O gene|O ,|O beclin|O 1|O using|O RT|O -|O PCR|O and|O Western|O blotting|O in|O an|O animal|O model|O .|O
Mean|O urinary|O protein|O of|O patients|O who|O returned|O to|O dialysis|O was|O 1|O .|O 26|O (|O 0|O .|O 5|O to|O 3|O .|O 5|O )|O g|O /|O d|O before|O and|O 4|O .|O 7|O (|O 3|O to|O 12|O )|O g|O /|O d|O after|O conversion|O (|O P|O =|O .|O 01|O )|O .|O
Improvement|O of|O levodopa|O -|O induced|O dyskinesia|B-Disease by|O propranolol|O in|O Parkinson|B-Disease '|I-Disease s|I-Disease disease|I-Disease .|O
A|O 14|O -|O year|O -|O old|O girl|O is|O reported|O with|O recurrent|O ,|O azithromycin|O -|O induced|O ,|O acute|O interstitial|B-Disease nephritis|Mention text="interstitial nephritis" start=17 end=19 type=Disease prob=null&Mention text="nephritis" start=18 end=19 type=Disease prob=null .|O
METHODS|O :|O A|O double|O -|O blind|O double|O -|O armed|O prospective|O study|O comprised|O 40|O patients|O who|O had|O uneventful|O sutureless|O phacoemulsification|O under|O sub|O -|O Tenon|O '|O s|O local|O infiltration|O of|O 3|O mL|O of|O plain|O lignocaine|O .|O
A|O respiratory|B-Disease arrest|I-Disease with|O severe|O desaturation|B-Disease and|O bradycardia|B-Disease occurred|O .|O
Continuous|O arteriovenous|O haemofiltration|O proved|O a|O valuable|O means|O of|O maintaining|O fluid|O and|O electrolyte|O balance|O .|O
The|O magnesium|O was|O stopped|O and|O she|O recovered|O over|O a|O few|O days|O .|O
Anaesthetists|O '|O nightmare|O :|O masseter|B-Disease spasm|I-Disease after|O induction|O in|O an|O undiagnosed|O case|O of|O myotonia|B-Disease congenita|I-Disease .|O
These|O patients|O showed|O persistently|O good|O graft|O function|O .|O
Lidocaine|O -|O induced|O cardiac|B-Disease asystole|I-Disease .|O
Three|O patients|O had|O no|O change|O and|O disease|O progressed|O in|O two|O .|O
The|O areas|O where|O calcitonin|O is|O most|O effective|O in|O decreasing|O locomotor|O activity|O are|O located|O in|O the|O hypothalamus|O and|O nucleus|O accumbens|O ,|O suggesting|O that|O these|O areas|O are|O the|O major|O sites|O of|O action|O of|O calcitonin|O in|O inhibiting|O amphetamine|O -|O induced|O locomotor|O activity|O .|O
Maximum|O tolerated|O dose|O in|O good|O -|O risk|O patients|O was|O 70|O mg|O /|O m2|O ,|O and|O in|O poor|O -|O risk|O patients|O ,|O 60|O mg|O /|O m2|O .|O
Mitochondrial|O injury|O may|O be|O involved|O in|O the|O progression|O of|O heart|B-Disease failure|I-Disease caused|O by|O adriamycin|O via|O the|O autophagy|O pathway|O .|O
CONCLUSIONS|O :|O Pharmacokinetic|O differences|O in|O statins|O are|O an|O important|O consideration|O for|O assessing|O the|O risk|O of|O potential|O drug|O interactions|O .|O
Dipyridamole|O -|O thallium|O -|O 201|O imaging|O is|O often|O performed|O in|O patients|O unable|O to|O exercise|O because|O of|O peripheral|B-Disease vascular|I-Disease disease|I-Disease .|O
Adriamycinol|O ,|O doxorubicin|O ,|O adriamycinone|O ,|O and|O tetrahydropyranyladriamycinol|O were|O the|O metabolites|O detected|O in|O plasma|O and|O the|O amount|O of|O doxorubicin|O was|O less|O than|O or|O equal|O to|O 10|O %|O of|O the|O total|O metabolites|O .|O
RESULTS|O :|O Subjects|O (|O n|O =|O 139|O )|O were|O 72|O women|O and|O 67|O men|O ,|O aged|O 40|O .|O 8|O +|O /|O -|O 12|O .|O 1|O years|O ,|O hospitalized|O for|O 24|O .|O 9|O +|O /|O -|O 23|O .|O 3|O days|O ,|O and|O given|O clozapine|O ,|O gradually|O increased|O to|O an|O average|O daily|O dose|O of|O 282|O +|O /|O -|O 203|O mg|O (|O 3|O .|O 45|O +|O /|O -|O 2|O .|O 45|O mg|O /|O kg|O )|O for|O 18|O .|O 9|O +|O /|O -|O 16|O .|O 4|O days|O .|O
The|O nitric|O oxide|O (|O NO|O )|O inhibitor|O nitro|O -|O L|O -|O arginine|O methyl|O ester|O (|O L|O -|O NAME|O )|O may|O act|O as|O an|O otoprotectant|O against|O high|B-Disease -|I-Disease frequency|I-Disease hearing|I-Disease loss|I-Disease caused|O by|O gentamicin|O ,|O but|O further|O studies|O are|O needed|O to|O confirm|O this|O .|O Aminoglycoside|O antibiotics|O are|O still|O widely|O used|O by|O virtue|O of|O their|O efficacy|O and|O low|O cost|O .|O
In|O addition|O ,|O a|O statistically|O significant|O reduction|O was|O also|O observed|O on|O the|O level|O of|O GABA|O and|O glycine|O but|O less|O than|O a|O drastic|O reduction|O of|O glutamate|O and|O aspartate|O level|O .|O
RESULTS|O :|O 3MA|O significantly|O improved|O cardiac|O function|O and|O reduced|O mitochondrial|O injury|O .|O
Delirium|B-Disease ,|O which|O may|O be|O induced|O by|O tricyclic|O drug|O therapy|O in|O the|O elderly|O ,|O can|O be|O caused|O by|O tricyclics|O with|O low|O anticholinergic|O potency|O .|O
After|O cessation|O of|O the|O sulfasalazine|O and|O completion|O of|O a|O six|O -|O week|O course|O of|O corticosteroids|O ,|O these|O problems|O resolved|O over|O a|O period|O of|O four|O to|O six|O months|O .|O
Calcitonin|O receptors|O are|O found|O in|O the|O brain|O ,|O and|O intracerebral|O infusions|O of|O calcitonin|O can|O produce|O behavioral|O effects|O .|O
SETTING|O :|O St|O .|O
A|O phase|O I|O study|O of|O 4|O '|O -|O 0|O -|O tetrahydropyranyladriamycin|O .|O Clinical|O pharmacology|O and|O pharmacokinetics|O .|O
These|O findings|O suggest|O that|O lowered|O serum|O prolactin|O levels|O in|O the|O early|O phase|O of|O bromocriptine|O treatment|O may|O result|O from|O an|O impaired|O secretion|O of|O prolactin|O due|O to|O decreasing|O numbers|O of|O cytoplasmic|O microtubules|O .|O
Ballistic|O and|O choreic|O dyskinesia|B-Disease were|O markedly|O ameliorated|O ,|O whereas|O dystonia|B-Disease was|O not|O .|O
We|O initiated|O a|O phase|O I|O /|O II|O trial|O to|O determine|O the|O response|O and|O toxicity|B-Disease of|O escalating|O paclitaxel|O doses|O combined|O with|O fixed|O -|O dose|O cisplatin|O with|O granulocyte|O colony|O -|O stimulating|O factor|O support|O in|O patients|O with|O untreated|O locally|O advanced|O inoperable|O head|B-Disease and|I-Disease neck|I-Disease carcinoma|I-Disease .|O
Neuromuscular|O monitoring|O was|O used|O in|O two|O patients|O .|O
In|O these|O 62|O patients|O ,|O no|O other|O causes|O for|O renal|B-Disease failure|I-Disease could|O be|O identified|O .|O
Neonatal|O cardiomyocytes|O were|O isolated|O from|O Sprague|O -|O Dawley|O rat|O hearts|O and|O randomly|O divided|O into|O controls|O ,|O an|O adriamycin|O -|O treated|O group|O ,|O and|O a|O 3MA|O plus|O adriamycin|O -|O treated|O group|O .|O
We|O retrospectively|O examined|O the|O records|O of|O 25|O renal|O transplant|O patients|O ,|O who|O developed|O or|O displayed|O increased|O proteinuria|B-Disease after|O SRL|O conversion|O .|O
An|O increase|O in|O the|O volume|O density|O of|O secretory|O granules|O and|O a|O decrease|O in|O the|O volume|O densities|O of|O rough|O endoplasmic|O reticulum|O and|O microtubules|O was|O determined|O by|O morphometric|O analysis|O ,|O suggesting|O that|O bromocriptine|O inhibits|O protein|O synthesis|O as|O well|O as|O bringing|O about|O a|O disturbance|O of|O the|O prolactin|O secretion|O .|O
Potential|O mechanisms|O of|O the|O pathophysiology|O are|O briefly|O discussed|O .|O
Neither|O the|O patient|O nor|O the|O anaesthetist|O was|O aware|O of|O the|O diagnosis|O before|O this|O potentially|O lethal|O complication|O occurred|O .|O
Accumulation|O of|O atracurium|O in|O the|O intravenous|O line|O led|O to|O recurarization|O after|O flushing|O the|O line|O in|O the|O recovery|O room|O .|O
Simvastatin|O is|O metabolized|O by|O CYP3A4|O .|O
This|O paper|O describes|O the|O clinical|O features|O of|O six|O children|O who|O developed|O the|O haemolytic|B-Disease -|I-Disease uraemic|I-Disease syndrome|I-Disease after|O treatment|O with|O metronidazole|O .|O
Immunohistochemical|O ,|O electron|O microscopic|O and|O morphometric|O studies|O of|O estrogen|O -|O induced|O rat|O prolactinomas|B-Disease after|O bromocriptine|O treatment|O .|O
Measurements|O included|O arterial|O ketone|O body|O ratio|O (|O AKBR|O ,|O aceto|O -|O acetate|O /|O 3|O -|O hydroxybutyrate|O )|O and|O clinical|O hepatic|O function|O parameters|O .|O
The|O renal|O function|O of|O 74|O children|O with|O malignant|B-Disease mesenchymal|I-Disease tumors|I-Disease in|O complete|O remission|O and|O who|O have|O received|O the|O same|O ifosfamide|O chemotherapy|O protocol|O (|O International|O Society|O of|O Pediatric|O Oncology|O Malignant|B-Disease Mesenchymal|I-Disease Tumor|I-Disease Study|O 84|O [|O SIOP|O MMT|O 84|O ]|O )|O were|O studied|O 1|O year|O after|O the|O completion|O of|O treatment|O .|O
Five|O grafts|O were|O lost|O and|O the|O patients|O returned|O to|O dialysis|O .|O
Postoperatively|O ,|O the|O patient|O refused|O DC|O cardioversion|O and|O was|O treated|O medically|O .|O
The|O patient|O was|O discharged|O and|O continued|O outpatient|O dialysis|O for|O 1|O month|O until|O his|O renal|O function|O recovered|O .|O
Butyrylcholinesterase|O gene|O mutations|O in|O patients|O with|O prolonged|O apnea|B-Disease after|O succinylcholine|O for|O electroconvulsive|O therapy|O .|O
These|O cases|O confirm|O the|O necessity|O of|O avoiding|O alcohol|O consumption|O as|O recommended|O in|O the|O instructions|O for|O use|O of|O Dormex|O and|O of|O preventing|O cutaneous|O contact|O during|O use|O .|O
Two|O pathologic|O complete|O responses|O were|O observed|O in|O patients|O who|O had|O achieved|O clinical|O complete|O responses|O .|O
Clinical|O nephrotoxicity|B-Disease of|O tobramycin|O and|O gentamicin|O .|O A|O prospective|O study|O .|O
In|O this|O study|O ,|O 62|O patients|O with|O confirmed|O initial|O normal|O renal|O function|O and|O treated|O with|O 2|O to|O 5|O mg|O /|O kg|O /|O day|O of|O gentamicin|O sulfate|O or|O tobramycin|O sulfate|O for|O a|O minimum|O of|O seven|O days|O were|O followed|O up|O prospectively|O for|O the|O development|O of|O aminoglycoside|O -|O related|O renal|B-Disease failure|I-Disease ,|O defined|O as|O at|O least|O a|O one|O -|O third|O reduction|O in|O renal|O function|O .|O
These|O findings|O indicate|O that|O gabapentin|O has|O a|O measurable|O antinociceptive|O effect|O and|O a|O stronger|O antihyperalgesic|O effect|O most|O evident|O in|O the|O brain|O areas|O undergoing|O deactivation|O ,|O thus|O supporting|O the|O concept|O that|O gabapentin|O is|O more|O effective|O in|O modulating|O nociceptive|O transmission|O when|O central|O sensitization|O is|O present|O .|O
During|O the|O SNP|O infusion|O the|O control|O animals|O demonstrated|O a|O progressive|O increase|B-Disease in|I-Disease blood|I-Disease pressure|I-Disease to|O 61|O torr|O ,|O whereas|O the|O saralasin|O -|O treated|O animals|O showed|O no|O change|O .|O
The|O aim|O of|O the|O present|O study|O was|O to|O find|O out|O whether|O TRI|O given|O repeatedly|O was|O able|O to|O induce|O adaptive|O changes|O in|O the|O dopaminergic|O and|O alpha1|O -|O adrenergic|O systems|O ,|O demonstrated|O by|O us|O previously|O for|O various|O antidepressants|O .|O
Its|O effect|O was|O determined|O in|O terms|O of|O attenuation|O of|O hearing|B-Disease loss|I-Disease ,|O measured|O by|O shifts|O in|O the|O auditory|O brainstem|O response|O threshold|O .|O
CONCLUSION|O :|O eleven|O of|O 13|O patients|O with|O a|O prolonged|O duration|O of|O action|O of|O succinylcholine|O had|O mutations|O in|O BCHE|O ,|O indicating|O that|O this|O is|O the|O possible|O reason|O for|O a|O prolonged|O period|O of|O apnea|B-Disease .|O
Renal|O function|O was|O investigated|O by|O measuring|O plasma|O and|O urinary|O electrolytes|O ,|O glucosuria|B-Disease ,|O proteinuria|B-Disease ,|O aminoaciduria|B-Disease ,|O urinary|O pH|O ,|O osmolarity|O ,|O creatinine|O clearance|O ,|O phosphate|O tubular|O reabsorption|O ,|O beta|O 2|O microglobulinuria|O ,|O and|O lysozymuria|O .|O
Of|O the|O nonepisode|O biopsies|O ,|O 7|O and|O 4|O biopsies|O showed|O minimal|O -|O type|O and|O mild|O -|O type|O chronic|O FK506|O nephropathy|B-Disease ,|O respectively|O .|O
However|O ,|O combinations|O of|O different|O therapeutic|O regimens|O require|O consideration|O of|O potential|O adverse|O reactions|O .|O
Results|O thus|O far|O suggest|O no|O dose|O -|O response|O effect|O for|O paclitaxel|O doses|O above|O 200|O mg|O /|O m2|O .|O
Isoniazid|O was|O the|O most|O frequent|O agent|O in|O drug|O -|O induced|O neuropathy|B-Disease .|O
Further|O research|O is|O needed|O to|O delineate|O the|O frequency|O of|O this|O troubling|O side|O effect|O and|O how|O best|O to|O treat|O it|O .|O
Thirty|O minutes|O after|O 99mTc|O -|O glucarate|O administration|O the|O standardised|O heart|O uptake|O value|O S|O (|O h|O )|O UV|O was|O 4|O .|O 7|O in|O infarcted|O rat|O heart|O which|O is|O six|O times|O more|O than|O in|O normal|O rats|O .|O
Treatment|O ,|O given|O every|O 21|O days|O for|O a|O maximum|O of|O three|O cycles|O ,|O consisted|O of|O paclitaxel|O by|O 3|O -|O hour|O infusion|O followed|O the|O next|O day|O by|O a|O fixed|O dose|O of|O cisplatin|O (|O 75|O mg|O /|O m2|O )|O .|O
Proteinuria|B-Disease increased|O from|O 0|O .|O 445|O (|O 0|O to|O 1|O .|O 5|O )|O g|O /|O d|O before|O conversion|O to|O 3|O .|O 2|O g|O /|O dL|O (|O 0|O .|O 2|O to|O 12|O )|O after|O conversion|O (|O P|O =|O 0|O .|O 001|O )|O .|O
We|O recommend|O objective|O neuromuscular|O monitoring|O during|O the|O first|O ECT|O .|O
Pharmacological|O modulation|O of|O pain|B-Disease -|O related|O brain|O activity|O during|O normal|O and|O central|O sensitization|O states|O in|O humans|O .|O
Five|O hours|O after|O exposure|O ,|O he|O developed|O disulfiram|O -|O like|O syndrome|O with|O flushing|B-Disease ,|O tachycardia|B-Disease ,|O and|O arterial|B-Disease hypotension|I-Disease after|O consuming|O three|O glasses|O of|O wine|O .|O
We|O report|O QTLs|O identified|O using|O a|O B6|O (|O host|O )|O x|O A|O /|O J|O (|O donor|O )|O CSS|O panel|O to|O localize|O genes|O involved|O in|O susceptibility|O to|O pilocarpine|O -|O induced|O seizures|B-Disease .|O
We|O describe|O a|O 15|O -|O yr|O -|O old|O girl|O who|O had|O orthotopic|O liver|O transplantation|O because|O of|O Wilson|B-Disease '|I-Disease s|I-Disease disease|I-Disease .|O
We|O suggest|O that|O our|O patient|O '|O s|O tubular|B-Disease dysfunction|I-Disease and|O myopathy|B-Disease may|O have|O resulted|O from|O mitochondrial|B-Disease dysfunction|I-Disease which|O is|O triggered|O by|O tacrolimus|O and|O augmented|O by|O lamivudine|O .|O
Abnormal|O brain|O responses|O to|O somatosensory|O stimuli|O have|O been|O found|O in|O patients|O with|O hyperalgesia|B-Disease as|O well|O as|O in|O normal|O subjects|O during|O experimental|O central|O sensitization|O .|O
Severe|O rhabdomyolysis|B-Disease and|O acute|B-Disease renal|I-Disease failure|I-Disease secondary|O to|O concomitant|O use|O of|O simvastatin|O ,|O amiodarone|O ,|O and|O atazanavir|O .|O
CONCLUSION|O :|O Autophagic|O cardiomyocyte|O death|B-Disease plays|O an|O important|O role|O in|O the|O pathogenesis|O of|O heart|B-Disease failure|I-Disease in|O rats|O induced|O by|O adriamycin|O .|O
The|O effects|O of|O PG|O -|O 9|O (|O 3alpha|O -|O tropyl|O 2|O -|O (|O p|O -|O bromophenyl|O )|O propionate|O )|O ,|O the|O acetylcholine|O releaser|O ,|O on|O memory|O processes|O and|O nerve|O growth|O factor|O (|O NGF|O )|O synthesis|O were|O evaluated|O .|O
Effects|O of|O long|O -|O term|O pretreatment|O with|O isoproterenol|O on|O bromocriptine|O -|O induced|O tachycardia|B-Disease in|O conscious|O rats|O .|O
A|O case|O of|O recurarization|O in|O the|O recovery|O room|O is|O reported|O .|O
Although|O paralysis|B-Disease after|O magnesium|O administration|O has|O been|O described|O in|O patients|O with|O known|O myasthenia|B-Disease gravis|I-Disease ,|O it|O has|O not|O previously|O been|O reported|O to|O be|O the|O initial|O or|O only|O manifestation|O of|O the|O disease|O .|O
Serum|O creatinine|O values|O did|O not|O change|O significantly|O :|O 1|O .|O 98|O +|O /|O -|O 0|O .|O 8|O mg|O /|O dL|O before|O SRL|O therapy|O and|O 2|O .|O 53|O +|O /|O -|O 1|O .|O 9|O mg|O /|O dL|O at|O last|O follow|O -|O up|O (|O P|O =|O .|O 14|O )|O .|O
More|O recently|O ,|O proteinuria|B-Disease has|O been|O reported|O as|O a|O consequence|O of|O sirolimus|O therapy|O ,|O although|O the|O mechanism|O has|O remained|O unclear|O .|O
Mean|O follow|O -|O up|O on|O SRL|O therapy|O was|O 20|O +|O /|O -|O 12|O (|O 6|O to|O 43|O )|O months|O .|O
The|O rat|O biodistribution|O studies|O showed|O a|O rapid|O blood|O clearance|O via|O the|O kidneys|O .|O
In|O 26|O .|O 5|O %|O of|O all|O the|O cases|O ,|O the|O aetiology|O of|O the|O neuropathy|B-Disease was|O undetermined|O .|O
A|O Phase|O I|O study|O of|O intravenous|O (|O IV|O )|O bolus|O 4|O '|O -|O 0|O -|O tetrahydropyranyladriamycin|O (|O Pirarubicin|O )|O was|O done|O in|O 55|O patients|O in|O good|O performance|O status|O with|O refractory|O tumors|B-Disease .|O
However|O ,|O only|O secretory|O granules|O showed|O the|O positive|O reaction|O products|O for|O prolactin|O 6|O h|O after|O bromocriptine|O treatment|O of|O the|O adenoma|B-Disease cells|O .|O
Adriamycin|O -|O induced|O autophagic|O cardiomyocyte|O death|B-Disease plays|O a|O pathogenic|O role|O in|O a|O rat|O model|O of|O heart|B-Disease failure|I-Disease .|O
Combined|O effects|O of|O prolonged|O prostaglandin|O E1|O -|O induced|O hypotension|B-Disease and|O haemodilution|B-Disease on|O human|O hepatic|O function|O .|O
Side|O effects|O of|O postoperative|O administration|O of|O methylprednisolone|O and|O gentamicin|O into|O the|O posterior|O sub|O -|O Tenon|O '|O s|O space|O .|O
The|O second|O case|O occurred|O in|O a|O 55|O -|O year|O -|O old|O farmer|O following|O cutaneous|O contact|O with|O Dormex|O .|O
The|O clinical|O course|O and|O histopathological|O results|O of|O the|O two|O cases|O are|O presented|O .|O
Tacrolimus|O ,|O MMF|O ,|O and|O steroids|O were|O given|O as|O immunosuppressant|O .|O
Therefore|O ,|O like|O VPA|O ,|O the|O finding|O that|O VPU|O could|O drastically|O reduce|O pilocarpine|O -|O induced|O increases|O in|O glutamate|O and|O aspartate|O should|O account|O ,|O at|O least|O partly|O ,|O for|O its|O anticonvulsant|O activity|O observed|O in|O pilocarpine|O -|O induced|O seizure|B-Disease in|O experimental|O animals|O .|O
The|O dose|O levels|O incorporate|O escalating|O paclitaxel|O doses|O ,|O and|O intrapatient|O escalations|O within|O a|O given|O dose|O level|O are|O permitted|O if|O toxicity|B-Disease permits|O .|O
We|O also|O assessed|O cell|O viability|O ,|O mitochondrial|O membrane|O potential|O changes|O and|O counted|O autophagic|O vacuoles|O in|O cultured|O cardiomyocytes|O .|O
Activity|O was|O noted|O in|O mesothelioma|B-Disease ,|O leiomyosarcoma|B-Disease ,|O and|O basal|B-Disease cell|I-Disease carcinoma|I-Disease .|O
The|O second|O episode|O was|O more|O severe|O than|O the|O first|O ;|O and|O although|O both|O were|O treated|O with|O intensive|O corticosteroid|O therapy|O ,|O renal|O function|O remained|O impaired|O .|O
METHODS|O :|O We|O used|O computerized|O pharmacy|O records|O to|O identify|O all|O adult|O psychiatric|B-Disease inpatients|O treated|O with|O clozapine|O (|O 1995|O -|O 96|O )|O ,|O reviewed|O their|O medical|O records|O to|O score|O incidence|O and|O severity|O of|O delirium|B-Disease ,|O and|O tested|O associations|O with|O potential|O risk|O factors|O .|O
In|O the|O mouse|O passive|O -|O avoidance|O test|O ,|O PG|O -|O 9|O (|O 10|O -|O 30|O mg|O /|O kg|O ,|O i|O .|O p|O .|O )|O ,|O administered|O 20|O min|O before|O the|O training|O session|O ,|O prevented|O amnesia|B-Disease induced|O by|O both|O the|O non|O selective|O antimuscarinic|O drug|O scopolamine|O and|O the|O M1|O -|O selective|O antagonist|O S|O -|O (|O -|O )|O -|O ET|O -|O 126|O .|O
Although|O tacrolimus|O was|O suspected|O to|O be|O the|O cause|O of|O late|O post|O -|O transplant|O renal|O acidosis|B-Disease and|O was|O replaced|O by|O sirolimus|O ,|O acidosis|B-Disease ,|O and|O electrolyte|O imbalance|O got|O worse|O .|O
At|O the|O end|O of|O the|O procedure|O ,|O Group|O A|O (|O n|O =|O 20|O )|O had|O 20|O mg|O /|O 0|O .|O 5|O mL|O of|O methylprednisolone|O and|O 10|O mg|O /|O 0|O .|O 5|O mL|O of|O gentamicin|O injected|O into|O the|O posterior|O sub|O -|O Tenon|O '|O s|O space|O and|O Group|O B|O (|O n|O =|O 20|O )|O had|O the|O same|O combination|O injected|O into|O the|O anterior|O sub|O -|O Tenon|O '|O s|O space|O .|O
Cardiovascular|B-Disease complications|I-Disease associated|O with|O terbutaline|O treatment|O for|O preterm|B-Disease labor|I-Disease .|O
Our|O case|O illustrates|O the|O serious|O consequences|O of|O medical|O errors|O that|O can|O be|O avoided|O through|O improved|O medication|O labeling|O and|O staff|O supervision|O .|O
Neither|O cardiac|O vagal|O nor|O sympathetic|O tone|O was|O altered|O by|O isoproterenol|O pretreatment|O .|O
Alopecia|B-Disease ,|O paresthesias|B-Disease ,|O and|O arthralgias|B-Disease /|O myalgias|B-Disease have|O occurred|O frequently|O ,|O but|O with|O one|O exception|O (|O a|O grade|O 3|O myalgia|B-Disease )|O they|O have|O been|O grade|O 1|O or|O 2|O .|O
The|O present|O study|O aimed|O to|O investigate|O the|O anticonvulsant|O activity|O as|O well|O as|O the|O effects|O on|O the|O level|O of|O hippocampal|O amino|O acid|O neurotransmitters|O (|O glutamate|O ,|O aspartate|O ,|O glycine|O and|O GABA|O )|O of|O N|O -|O (|O 2|O -|O propylpentanoyl|O )|O urea|O (|O VPU|O )|O in|O comparison|O to|O its|O parent|O compound|O ,|O valproic|O acid|O (|O VPA|O )|O .|O
Lamivudine|O was|O added|O because|O of|O de|O nova|O hepatitis|B-Disease B|I-Disease infection|I-Disease during|O her|O follow|O -|O up|O .|O
The|O patient|O cohort|O (|O 14|O men|O ,|O 11|O women|O )|O was|O treated|O with|O SRL|O as|O conversion|O therapy|O ,|O due|O to|O chronic|B-Disease allograft|I-Disease nephropathy|I-Disease (|O CAN|B-Disease )|O (|O n|O =|O 15|O )|O neoplasia|B-Disease (|O n|O =|O 8|O )|O ;|O Kaposi|B-Disease '|I-Disease s|I-Disease sarcoma|I-Disease ,|O Four|O skin|B-Disease cancers|I-Disease ,|O One|O intestinal|B-Disease tumors|I-Disease ,|O One|O renal|B-Disease cell|I-Disease carsinom|I-Disease )|O or|O BK|O virus|O nephropathy|B-Disease (|O n|O =|O 2|O )|O .|O
Laryngeal|O electromyography|O (|O thyroarytenoid|O muscle|O )|O showed|O ample|O denervation|O potentials|O .|O
In|O control|O rats|O ,|O intravenous|O bromocriptine|O (|O 150|O microg|O /|O kg|O )|O induced|O significant|O hypotension|B-Disease and|O tachycardia|B-Disease .|O
Rebound|O hypertensive|B-Disease after|O sodium|O nitroprusside|O prevented|O by|O saralasin|O in|O rats|O .|O
Eleven|O responding|O patients|O had|O subsequent|O surgery|O /|O radiotherapy|O or|O radical|O radiotherapy|O .|O
Combined|O effects|O of|O prolonged|O prostaglandin|O E1|O (|O PGE1|O )|O -|O induced|O hypotension|B-Disease and|O haemodilution|B-Disease on|O hepatic|O function|O were|O studied|O in|O 30|O patients|O undergoing|O hip|O surgery|O .|O
CONCLUSIONS|O :|O The|O administration|O of|O methylprednisolone|O and|O gentamicin|O in|O the|O posterior|O sub|O -|O Tenon|O '|O s|O space|O was|O related|O to|O a|O high|O incidence|O of|O side|O effects|O including|O nausea|B-Disease ,|I-Disease vomiting|I-Disease ,|O and|O headache|B-Disease .|O
Three|O hundred|O fifty|O -|O five|O adult|O male|O CSS|O mice|O ,|O 58|O B6|O ,|O and|O 39|O A|O /|O J|O were|O tested|O for|O susceptibility|O to|O pilocarpine|O -|O induced|O seizures|B-Disease .|O
Urinary|O excretion|O of|O Pirarubicin|O in|O the|O first|O 24|O hours|O was|O less|O than|O or|O equal|O to|O 10|O %|O .|O
Disulfiram|O -|O like|O syndrome|O after|O hydrogen|O cyanamide|O professional|O skin|O exposure|O :|O two|O case|O reports|O in|O France|O .|O
Many|O new|O serotonergic|O antidepressants|O have|O been|O introduced|O over|O the|O past|O decade|O .|O
A|O review|O of|O all|O reported|O cases|O in|O the|O literature|O is|O given|O .|O
While|O the|O involvement|O of|O metronidazole|O in|O the|O aetiology|O of|O the|O haemolytic|B-Disease -|I-Disease uraemic|I-Disease syndrome|I-Disease is|O not|O established|O firmly|O ,|O the|O action|O of|O this|O drug|O in|O sensitizing|O tissues|O to|O oxidation|O injury|O and|O the|O reported|O evidence|O of|O oxidation|O changes|O in|O the|O haemolytic|B-Disease -|I-Disease uraemic|I-Disease syndrome|I-Disease suggest|O a|O possible|O link|O between|O metronidazole|O treatment|O and|O some|O cases|O of|O the|O haemolytic|B-Disease -|I-Disease uraemic|I-Disease syndrome|I-Disease .|O
TRI|O was|O given|O to|O male|O Wistar|O rats|O and|O male|O Albino|O Swiss|O mice|O perorally|O twice|O daily|O for|O 14|O days|O .|O
The|O morphological|O analysis|O of|O the|O kidneys|O included|O a|O semi|O -|O quantitative|O scoring|O system|O analysing|O the|O degree|O of|O striped|O fibrosis|B-Disease ,|O subcapsular|O fibrosis|B-Disease and|O the|O number|O of|O basophilic|O tubules|O ,|O plus|O an|O additional|O stereological|O analysis|O of|O the|O total|O grade|O of|O fibrosis|B-Disease in|O the|O cortex|O stained|O with|O Sirius|O Red|O .|O
Twenty|O -|O six|O had|O minimal|O prior|O therapy|O (|O good|O risk|O )|O ,|O 23|O had|O extensive|O prior|O therapy|O (|O poor|O risk|O )|O ,|O and|O six|O had|O renal|B-Disease and|I-Disease /|I-Disease or|I-Disease hepatic|I-Disease dysfunction|I-Disease .|O
Laboratory|O evaluations|O ,|O including|O head|O CT|O scan|O ,|O were|O normal|O .|O
This|O was|O accounted|O for|O by|O a|O significant|O number|O of|O depressions|B-Disease occurring|O in|O methyl|O dopa|O treated|O patients|O with|O psychiatric|B-Disease histories|O .|O
Few|O days|O later|O ,|O the|O patient|O used|O another|O 200|O mg|O ketoconazole|O tablet|O ,|O and|O within|O an|O hour|O experienced|O a|O similar|O clinical|O picture|O ,|O which|O resolved|O again|O spontaneously|O within|O hours|O .|O
In|O previous|O experiments|O we|O found|O that|O decreases|O in|O food|O intake|O were|O induced|O by|O local|O administration|O of|O calcitonin|O into|O several|O hypothalamic|O sites|O and|O into|O the|O nucleus|O accumbens|O .|O
She|O noticed|O hoarseness|B-Disease and|O distally|O accentuated|O motor|O and|O sensory|O dysfunction|O after|O she|O had|O recovered|O from|O this|O state|O .|O
Dipyridamole|O significantly|O increased|O coronary|O blood|O flow|O before|O and|O after|O 7|O .|O 5|O or|O 15|O mm|O /|O kg|O i|O .|O v|O .|O pentoxifylline|O (|O p|O less|O than|O 0|O .|O 002|O )|O .|O
The|O prolactinoma|B-Disease cells|O at|O this|O time|O were|O well|O granulated|O ,|O with|O vesiculated|O rough|O endoplasmic|O reticulum|O and|O markedly|O dilated|O Golgi|O cisternae|O .|O
Clinically|O ,|O the|O onset|O was|O characterized|O by|O the|O signs|O of|O opistothonus|B-Disease ,|I-Disease sensory|I-Disease and|I-Disease motor|I-Disease dysfunction|I-Disease and|O ascending|O paralysis|B-Disease .|O
Regional|O localization|O of|O the|O antagonism|O of|O amphetamine|O -|O induced|O hyperactivity|B-Disease by|O intracerebral|O calcitonin|O injections|O .|O
Pneumonitis|B-Disease ,|O bilateral|O pleural|B-Disease effusions|I-Disease ,|O echocardiographic|O evidence|O of|O cardiac|B-Disease tamponade|I-Disease ,|O and|O positive|O autoantibodies|O developed|O in|O a|O 43|O -|O year|O -|O old|O man|O ,|O who|O was|O receiving|O long|O -|O term|O sulfasalazine|O therapy|O for|O chronic|O ulcerative|B-Disease colitis|I-Disease .|O
A|O further|O deterioration|O was|O seen|O when|O CsA|O was|O combined|O with|O either|O FK506|O or|O SRL|O ,|O whereas|O the|O GFR|O remained|O unchanged|O in|O the|O group|O treated|O with|O FK506|O plus|O SRL|O when|O compared|O with|O treatment|O with|O any|O of|O the|O single|O substances|O .|O
CSS|O mapping|O suggests|O seizure|B-Disease susceptibility|O loci|O on|O mouse|O Chromosomes|O 10|O and|O 18|O .|O
Although|O urinary|B-Disease incontinence|I-Disease is|O listed|O as|O one|O side|O effect|O of|O these|O drugs|O in|O their|O package|O inserts|O there|O is|O only|O one|O report|O in|O the|O literature|O .|O
Hypertensive|B-Disease patients|O with|O psychiatric|B-Disease histories|O had|O a|O higher|O prevalence|O of|O depression|B-Disease than|O the|O comparison|O patients|O .|O
A|O 49|O -|O year|O -|O old|O woman|O was|O transferred|O to|O our|O department|O because|O of|O quadriparesis|B-Disease ,|O lancinating|O pain|B-Disease ,|O sensory|B-Disease loss|I-Disease ,|O and|O paresthesia|B-Disease of|O the|O distal|O limbs|O .|O
Chronic|O FK506|O nephropathy|B-Disease consisted|O of|O rough|O and|O foamy|O tubular|O vacuolization|O (|O 5|O biopsies|O )|O ,|O arteriolopathy|O (|O angiodegeneration|O of|O the|O arteriolar|O wall|O ;|O 20|O biopsies|O )|O ,|O focal|B-Disease segmental|I-Disease glomerulosclerosis|I-Disease (|O 4|O biopsies|O )|O and|O the|O striped|O form|O of|O interstitial|B-Disease fibrosis|I-Disease (|O 11|O biopsies|O )|O .|O
QRS|O without|O preexcitation|O ,|O caused|O by|O junctional|O escape|O beats|O after|O verapamil|O or|O unidirectional|O antegrade|O block|O of|O accessory|O pathway|O after|O catheter|O ablation|O ,|O established|O frequent|O AVRT|B-Disease attack|O .|O
The|O results|O showed|O a|O high|O prevalence|O of|O depression|B-Disease in|O both|O groups|O of|O patients|O ,|O with|O no|O preponderance|O in|O the|O hypertensive|B-Disease group|O .|O
The|O block|O was|O successful|O and|O surgery|O was|O conducted|O as|O scheduled|O despite|O persisting|O atrial|B-Disease fibrillation|I-Disease .|O
This|O study|O was|O conducted|O to|O examine|O whether|O prolonged|O pretreatment|O with|O isoproterenol|O could|O abolish|O bromocriptine|O -|O induced|O tachycardia|B-Disease in|O conscious|O rats|O .|O
Infarct|B-Disease -|O avid|O radiopharmaceuticals|O are|O necessary|O for|O rapid|O and|O timely|O diagnosis|O of|O acute|O myocardial|B-Disease infarction|I-Disease .|O
The|O overall|O response|O rate|O is|O 72|O %|O .|O
Electron|O microscopy|O disclosed|O many|O secretory|O granules|O ,|O slightly|O distorted|O rough|O endoplasmic|O reticulum|O ,|O and|O partially|O dilated|O Golgi|O cisternae|O in|O the|O prolactinoma|B-Disease cells|O .|O
The|O mechanism|O of|O its|O antidepressant|O activity|O is|O still|O unknown|O .|O
Antihypertensive|O drugs|O and|O depression|B-Disease :|O a|O reappraisal|O .|O
Both|O patients|O recovered|O quickly|O after|O stopping|O glyburide|O therapy|O and|O have|O remained|O well|O for|O a|O follow|O -|O up|O period|O of|O 1|O year|O .|O
Further|O studies|O of|O specifically|O elderly|O patients|O are|O now|O required|O to|O establish|O safer|O and|O more|O appropriate|O guidelines|O for|O drug|O therapy|O .|O
Glyburide|O -|O induced|O hepatitis|B-Disease .|O
Catecholamine|O -|O induced|O cardiomyopathy|B-Disease due|O to|O chronic|O excess|O of|O endogenous|O catecholamines|O has|O been|O recognized|O for|O decades|O as|O a|O clinical|O phenomenon|O .|O
None|O of|O them|O had|O received|O cisplatin|O chemotherapy|O .|O
BACKGROUND|O :|O patients|O undergoing|O electroconvulsive|O therapy|O (|O ECT|O )|O often|O receive|O succinylcholine|O as|O part|O of|O the|O anesthetic|O procedure|O .|O
Following|O discontinuation|O of|O SNP|O ,|O blood|O pressure|O in|O the|O control|O animals|O rebounded|O to|O 94|O torr|O ,|O as|O compared|O with|O 78|O torr|O in|O the|O saralasin|O -|O treated|O rats|O .|O
Using|O functional|O magnetic|O resonance|O imaging|O (|O fMRI|O )|O in|O normal|O volunteers|O ,|O we|O studied|O the|O gabapentin|O -|O induced|O modulation|O of|O brain|O activity|O in|O response|O to|O nociceptive|O mechanical|O stimulation|O of|O normal|O skin|O and|O capsaicin|O -|O induced|O secondary|B-Disease hyperalgesia|I-Disease .|O
In|O contrast|O ,|O reports|O of|O myocardial|B-Disease dysfunction|I-Disease due|O to|O acute|O iatrogenic|O overdose|B-Disease are|O rare|O .|O
Therefore|O ,|O we|O studied|O the|O hyperemic|O response|O to|O dipyridamole|O in|O seven|O open|O -|O chest|O anesthetized|O dogs|O after|O pretreatment|O with|O either|O pentoxifylline|O (|O 0|O ,|O 7|O .|O 5|O ,|O or|O 15|O mg|O /|O kg|O i|O .|O v|O .|O )|O or|O theophylline|O (|O 3|O mg|O /|O kg|O i|O .|O v|O .|O )|O .|O
There|O was|O a|O significant|O 40|O %|O improvement|O in|O the|O dyskinesia|B-Disease score|O without|O increase|O of|O parkinsonian|B-Disease motor|B-Disease disability|I-Disease .|O
Postoperatively|O ,|O all|O patients|O were|O assessed|O for|O symptoms|O of|O nausea|B-Disease ,|I-Disease vomiting|I-Disease ,|O and|O headache|B-Disease .|O
A|O case|O of|O metabolic|B-Disease acidosis|Mention text="metabolic acidosis" start=3 end=5 type=Disease prob=null&Mention text="acidosis" start=4 end=5 type=Disease prob=null ,|O acute|B-Disease renal|I-Disease failure|I-Disease and|I-Disease hepatic|I-Disease failure|I-Disease following|O paracetamol|O ingestion|O is|O presented|O .|O
Morphometric|O analysis|O revealed|O that|O the|O volume|O density|O of|O secretory|O granules|O increased|O ,|O while|O the|O volume|O density|O of|O cytoplasmic|O microtubules|O decreased|O .|O
Before|O conversion|O 8|O (|O 32|O %|O )|O patients|O had|O no|O proteinuria|B-Disease ,|O whereas|O afterwards|O all|O patients|O had|O proteinuria|B-Disease .|O
The|O remaining|O seven|O patients|O had|O isolated|O beta|O 2|O microglobulinuria|O .|O
Amiodarone|O and|O atazanavir|O are|O recognized|O CYP3A4|O inhibitors|O .|O
All|O adverse|O effects|O were|O self|O -|O limiting|O .|O
Guillain|B-Disease -|I-Disease Barr|I-Disease syndrome|I-Disease was|O the|O commonest|O identifiable|O cause|O (|O 15|O .|O 6|O %|O )|O ,|O accounting|O for|O half|O of|O the|O cases|O with|O motor|B-Disease neuropathy|I-Disease .|O
Five|O patients|O displayed|O CAN|B-Disease and|O Kaposi|B-Disease '|I-Disease s|I-Disease sarcoma|I-Disease .|O
For|O glyburide|O ,|O a|O second|O -|O generation|O sulfonylurea|O ,|O only|O two|O brief|O reports|O of|O hepatotoxicity|B-Disease exist|O .|O
Of|O 18|O patients|O evaluable|O for|O response|O ,|O seven|O (|O 39|O %|O )|O achieved|O a|O complete|O response|O and|O six|O (|O 33|O %|O )|O achieved|O a|O partial|O response|O .|O
After|O intravenous|O administration|O of|O labetalol|O ,|O metoprolol|O and|O midazolam|O the|O patient|O '|O s|O condition|O improved|O ,|O and|O 15|O min|O later|O he|O woke|O up|O .|O
There|O was|O no|O serologic|O evidence|O of|O viral|B-Disease infection|I-Disease ,|O and|O a|O liver|O biopsy|O sample|O showed|O a|O histologic|O pattern|O consistent|O with|O drug|B-Disease -|I-Disease induced|I-Disease hepatitis|Mention text="drug-induced hepatitis" start=20 end=24 type=Disease prob=null&Mention text="hepatitis" start=23 end=24 type=Disease prob=null .|O
Myelosuppression|B-Disease was|O more|O in|O patients|O with|O hepatic|B-Disease dysfunction|I-Disease .|O
The|O aim|O of|O this|O study|O was|O to|O examine|O further|O the|O renal|O function|O ,|O including|O morphological|O analysis|O of|O the|O kidneys|O of|O male|O Sprague|O -|O Dawley|O rats|O treated|O with|O either|O cyclosporine|O A|O (|O CsA|O )|O ,|O tacrolimus|O (|O FK506|O )|O or|O SRL|O as|O monotherapies|O or|O in|O different|O combinations|O .|O
The|O abruptness|O of|O the|O renal|B-Disease failure|I-Disease and|O its|O reversibility|O within|O days|O suggests|O that|O there|O was|O a|O functional|O component|O to|O the|O renal|B-Disease dysfunction|I-Disease .|O
It|O has|O been|O shown|O that|O bromocriptine|O -|O induced|O tachycardia|B-Disease ,|O which|O persisted|O after|O adrenalectomy|O ,|O is|O (|O i|O )|O mediated|O by|O central|O dopamine|O D2|O receptor|O activation|O and|O (|O ii|O )|O reduced|O by|O 5|O -|O day|O isoproterenol|O pretreatment|O ,|O supporting|O therefore|O the|O hypothesis|O that|O this|O effect|O is|O dependent|O on|O sympathetic|O outflow|O to|O the|O heart|O .|O
DISCUSSION|O :|O The|O risk|O of|O rhabdomyolysis|B-Disease is|O increased|O in|O the|O presence|O of|O concomitant|O drugs|O that|O inhibit|O simvastatin|O metabolism|O .|O
To|O date|O ,|O 23|O men|O with|O a|O median|O age|O of|O 50|O years|O and|O good|O performance|O status|O have|O entered|O the|O trial|O .|O
We|O then|O examined|O the|O morphology|O ,|O expression|O of|O beclin|O 1|O gene|O ,|O mitochondrial|O permeability|O transition|O (|O MPT|O )|O ,|O and|O Na|O +|O -|O K|O +|O ATPase|O activity|O in|O vivo|O .|O
Both|O the|O temporal|O relationship|O of|O events|O and|O the|O response|O to|O treatment|O suggest|O that|O a|O rapid|O systemic|O absorption|O of|O mepivacaine|O with|O adrenaline|O and|O /|O or|O interaction|O of|O these|O drugs|O with|O the|O patient|O '|O s|O cardiovascular|O medications|O were|O responsible|O for|O the|O perioperative|O complications|O .|O
Secondary|B-Disease hyperalgesia|I-Disease shares|O clinical|O characteristics|O with|O neurogenic|B-Disease hyperalgesia|I-Disease in|O patients|O with|O neuropathic|B-Disease pain|I-Disease .|O
Isoproterenol|O pretreatment|O for|O 15|O days|O caused|O cardiac|B-Disease hypertrophy|I-Disease without|O affecting|O baseline|O blood|O pressure|O and|O heart|O rate|O .|O
We|O report|O on|O two|O fatal|O cases|O of|O accidental|O intrathecal|O vincristine|O instillation|O in|O a|O 5|O -|O year|O old|O girl|O with|O recurrent|O acute|B-Disease lymphoblastic|I-Disease leucemia|I-Disease and|O a|O 57|O -|O year|O old|O man|O with|O lymphoblastic|B-Disease lymphoma|I-Disease .|O
The|O patient|O recovered|O .|O
In|O isolated|O perfused|O heart|O preparations|O from|O isoproterenol|O -|O pretreated|O rats|O ,|O the|O isoproterenol|O -|O induced|O maximal|O increase|O in|O left|O ventricular|O systolic|O pressure|O was|O significantly|O reduced|O ,|O compared|O with|O saline|O -|O pretreated|O rats|O (|O the|O EC50|O of|O the|O isoproterenol|O -|O induced|O increase|O in|O left|O ventricular|O systolic|O pressure|O was|O enhanced|O approximately|O 22|O -|O fold|O )|O .|O
The|O semi|O -|O quantitative|O scoring|O was|O significantly|O worst|O in|O the|O group|O treated|O with|O CsA|O plus|O SRL|O (|O P|O <|O 0|O .|O 001|O compared|O with|O controls|O )|O and|O the|O analysis|O of|O the|O total|O grade|O of|O fibrosis|B-Disease also|O showed|O the|O highest|O proportion|O in|O the|O same|O group|O and|O was|O significantly|O different|O from|O controls|O (|O P|O <|O 0|O .|O 02|O )|O .|O
It|O is|O suggested|O that|O the|O patient|O had|O sulfasalazine|O -|O induced|O lupus|B-Disease ,|O which|O manifested|O with|O serositis|B-Disease and|O pulmonary|O parenchymal|O involvement|O in|O the|O absence|O of|O joint|O symptoms|O .|O
The|O patient|O had|O no|O apparent|O associated|O conditions|O which|O might|O have|O predisposed|O him|O to|O the|O development|O of|O bradyarrhythmias|B-Disease ;|O and|O ,|O thus|O ,|O this|O probably|O represented|O a|O true|O idiosyncrasy|O to|O lidocaine|O .|O
Myasthenia|B-Disease gravis|I-Disease presenting|O as|O weakness|O after|O magnesium|O administration|O .|O
The|O area|O under|O the|O curve|O was|O 537|O +|O /|O -|O 149|O ng|O /|O ml|O x|O hours|O ,|O volume|O of|O distribution|O (|O Vd|O )|O 3504|O +|O /|O -|O 644|O l|O /|O m2|O ,|O and|O total|O clearance|O (|O ClT|O )|O was|O 204|O +|O 39|O .|O 3|O l|O /|O hour|O /|O m2|O .|O
Recurrent|O reversible|O acute|B-Disease renal|I-Disease failure|I-Disease from|O amphotericin|O .|O
A|O 77|O -|O y|O -|O old|O patient|O developed|O weakness|B-Disease of|I-Disease extremities|I-Disease ,|O legs|B-Disease paralysis|I-Disease ,|O dysarthria|B-Disease and|O tremor|B-Disease 1|O h|O after|O ingestion|O of|O 200|O mg|O ketoconazole|O for|O the|O first|O time|O in|O his|O life|O .|O
All|O complaints|O faded|O away|O within|O 24|O h|O .|O
BACKGROUND|O :|O We|O clinically|O and|O pathologically|O analyzed|O renal|O allografts|O from|O 1|O 9|O renal|O transplant|O patients|O treated|O with|O tacrolimus|O (|O FK506|O )|O for|O more|O than|O 1|O year|O .|O
Histological|O and|O immunohistochemical|O investigations|O (|O HE|O -|O LFB|O ,|O CD|O -|O 68|O ,|O Neurofilament|O )|O revealed|O degeneration|B-Disease of|I-Disease myelin|I-Disease and|I-Disease axons|I-Disease as|O well|O as|O pseudocystic|B-Disease transformation|I-Disease in|O areas|O exposed|O to|O vincristine|O ,|O accompanied|O by|O secondary|O changes|O with|O numerous|O prominent|O macrophages|O .|O
BACKGROUND|O :|O A|O 72|O -|O year|O -|O old|O white|O man|O with|O underlying|O human|B-Disease immunodeficiency|I-Disease virus|I-Disease ,|O atrial|B-Disease fibrillation|I-Disease ,|O coronary|B-Disease artery|I-Disease disease|I-Disease ,|O and|O hyperlipidemia|B-Disease presented|O with|O generalized|O pain|B-Disease ,|O fatigue|B-Disease ,|O and|O dark|O orange|O urine|O for|O 3|O days|O .|O
The|O duration|O of|O apnea|B-Disease was|O compared|O with|O published|O data|O on|O normal|O subjects|O .|O
Delirium|B-Disease during|O clozapine|O treatment|O :|O incidence|O and|O associated|O risk|O factors|O .|O
Simvastatin|O ,|O amiodarone|O ,|O and|O the|O patient|O '|O s|O human|B-Disease immunodeficiency|I-Disease virus|I-Disease medications|O were|O all|O temporarily|O discontinued|O and|O the|O patient|O was|O given|O forced|O alkaline|O diuresis|O and|O started|O on|O dialysis|O .|O
She|O was|O not|O an|O alcoholic|O .|O
BACKGROUND|O :|O The|O mechanisms|O underlying|O heart|B-Disease failure|I-Disease induced|O by|O adriamycin|O are|O very|O complicated|O and|O still|O unclear|O .|O
A|O better|O controlled|O regimen|O for|O administering|O vincristine|O and|O intrathecal|O chemotherapy|O is|O recommended|O .|O
99mTc|O -|O glucarate|O for|O detection|O of|O isoproterenol|O -|O induced|O myocardial|B-Disease infarction|I-Disease in|O rats|O .|O
With|O paclitaxel|O doses|O of|O 200|O mg|O /|O m2|O and|O higher|O ,|O granulocyte|O colony|O -|O stimulating|O factor|O 5|O micrograms|O /|O kg|O /|O d|O is|O given|O (|O days|O 4|O through|O 12|O )|O .|O
Heavy|O proteinuria|B-Disease was|O common|O after|O the|O use|O of|O SRL|O as|O rescue|O therapy|O for|O renal|O transplantation|O .|O
This|O was|O a|O case|O of|O acute|O palsy|B-Disease of|O the|O recurrent|O laryngeal|O nerve|O and|O superimposed|O severe|O acute|O sensorimotor|O axonal|O polyneuropathy|B-Disease caused|O by|O high|O -|O dose|O disulfiram|O intoxication|O .|O
Laryngoscopy|O revealed|O asymmetric|O vocal|O fold|O movements|O during|O phonation|O .|O
The|O first|O case|O involved|O a|O 59|O -|O year|O -|O old|O man|O who|O used|O Dormex|O ,|O which|O contains|O hydrogen|O cyanamide|O ,|O without|O protection|O after|O consuming|O a|O large|O amount|O of|O alcohol|O during|O a|O meal|O .|O
The|O recommended|O starting|O dose|O for|O Phase|O II|O trials|O is|O 60|O mg|O /|O m2|O IV|O bolus|O every|O 3|O weeks|O .|O
CONCLUSIONS|O :|O This|O study|O demonstrates|O that|O chronic|O FK506|O nephropathy|B-Disease consists|O primarily|O of|O arteriolopathy|O manifesting|O as|O insudative|O hyalinosis|O of|O the|O arteriolar|O wall|O ,|O and|O suggests|O that|O mild|O -|O type|O chronic|O FK506|O nephropathy|B-Disease is|O a|O condition|O which|O may|O lead|O to|O deterioration|O of|O renal|O allograft|O function|O .|O
We|O conclude|O that|O pentoxyifylline|O does|O not|O inhibit|O dipyridamole|O -|O induced|O coronary|O hyperemia|B-Disease even|O at|O high|O doses|O .|O
RESULTS|O :|O in|O 11|O patients|O ,|O mutations|O were|O found|O in|O the|O BCHE|O gene|O ,|O the|O K|O -|O variant|O being|O the|O most|O frequent|O .|O
Delirium|B-Disease was|O diagnosed|O in|O 14|O (|O 10|O .|O 1|O %|O incidence|O ,|O or|O 1|O .|O 48|O cases|O /|O person|O -|O years|O of|O exposure|O )|O ;|O 71|O .|O 4|O %|O of|O cases|O were|O moderate|O or|O severe|O .|O
After|O her|O strength|O returned|O ,|O repetitive|O stimulation|O was|O normal|O ,|O but|O single|O fiber|O EMG|O revealed|O increased|O jitter|O and|O blocking|O .|O
Abnormal|O processing|O of|O somatosensory|O inputs|O in|O the|O central|O nervous|O system|O (|O central|O sensitization|O )|O is|O the|O mechanism|O accounting|O for|O the|O enhanced|O pain|B-Disease sensitivity|O in|O the|O skin|O surrounding|O tissue|B-Disease injury|I-Disease (|O secondary|B-Disease hyperalgesia|I-Disease )|O .|O
The|O role|O of|O the|O renin|O -|O -|O angiotensin|O system|O in|O the|O maintenance|O of|O blood|O pressure|O during|O halothane|O anesthesia|O and|O sodium|O nitroprusside|O (|O SNP|O )|O -|O induced|O hypotension|B-Disease was|O evaluated|O .|O
During|O culture|O ,|O no|O morphological|O changes|O were|O found|O at|O effective|O concentrations|O of|O PG|O -|O 9|O .|O
We|O studied|O a|O patient|O with|O no|O prior|O history|O of|O neuromuscular|B-Disease disease|I-Disease who|O became|O virtually|O quadriplegic|B-Disease after|O parenteral|O magnesium|O administration|O for|O preeclampsia|B-Disease .|O
Some|O of|O the|O factors|O related|O to|O the|O clinical|O presentation|O and|O pathogenesis|O of|O the|O neuropathies|B-Disease are|O briefly|O discussed|O .|O
METHODS|O :|O For|O a|O period|O of|O 2|O weeks|O ,|O CsA|O 15|O mg|O /|O kg|O /|O day|O (|O given|O orally|O )|O ,|O FK506|O 3|O .|O 0|O mg|O /|O kg|O /|O day|O (|O given|O orally|O )|O or|O SRL|O 0|O .|O 4|O mg|O /|O kg|O /|O day|O (|O given|O intraperitoneally|O )|O was|O administered|O once|O a|O day|O as|O these|O doses|O have|O earlier|O been|O found|O to|O achieve|O a|O significant|O immunosuppressive|O effect|O in|O Sprague|O -|O Dawley|O rats|O .|O
BACKGROUND|O :|O Sirolimus|O (|O SRL|O )|O may|O supplement|O calcineurin|O inhibitors|O in|O clinical|O organ|O transplantation|O .|O
Memory|O facilitation|O and|O stimulation|O of|O endogenous|O nerve|O growth|O factor|O synthesis|O by|O the|O acetylcholine|O releaser|O PG|O -|O 9|O .|O
The|O patients|O were|O randomly|O allocated|O to|O one|O of|O three|O groups|O ;|O those|O in|O group|O A|O (|O n|O =|O 10|O )|O were|O subjected|O to|O controlled|O hypotension|B-Disease alone|O ,|O those|O in|O group|O B|O (|O n|O =|O 10|O )|O to|O haemodilution|B-Disease alone|O and|O those|O in|O group|O C|O (|O n|O =|O 10|O )|O to|O both|O controlled|O hypotension|B-Disease and|O haemodilution|B-Disease .|O
Hydrogen|O cyanamide|O is|O a|O plant|O growth|O regulator|O used|O in|O agriculture|O to|O induce|O bud|O break|O in|O fruit|O trees|O .|O
Peripheral|B-Disease neuropathy|I-Disease due|O to|O nutritional|B-Disease deficiency|I-Disease of|O thiamine|O and|O riboflavin|O was|O common|O (|O 10|O .|O 1|O %|O )|O and|O presented|O mainly|O as|O sensory|O and|O sensori|B-Disease -|I-Disease motor|I-Disease neuropathy|I-Disease .|O
SRL|O was|O started|O at|O a|O mean|O of|O 78|O +|O /|O -|O 42|O (|O 15|O to|O 163|O )|O months|O after|O transplantation|O .|O
Patients|O who|O are|O unusually|O sensitive|O to|O the|O neuromuscular|O effects|O of|O magnesium|O should|O be|O suspected|O of|O having|O an|O underlying|O disorder|B-Disease of|I-Disease neuromuscular|I-Disease transmission|I-Disease .|O
In|O a|O number|O of|O treatment|O protocols|O where|O SRL|O was|O combined|O with|O a|O calcineurin|O inhibitor|O indications|O of|O a|O synergistic|O nephrotoxic|B-Disease effect|O were|O described|O .|O
In|O the|O present|O paper|O the|O authors|O describe|O 2|O female|O patients|O who|O developed|O incontinence|B-Disease secondary|O to|O the|O selective|O serotonin|O reuptake|O inhibitors|O paroxetine|O and|O sertraline|O ,|O as|O well|O as|O a|O third|O who|O developed|O this|O side|O effect|O on|O venlafaxine|O .|O
We|O propose|O that|O amphotericin|O ,|O in|O the|O setting|O of|O reduced|O effective|O arterial|O volume|O ,|O may|O activate|O tubuloglomerular|O feedback|O ,|O thereby|O contributing|O to|O acute|B-Disease renal|I-Disease failure|I-Disease .|O
Seizure|B-Disease susceptibility|O varies|O among|O inbred|O mouse|O strains|O .|O
It|O increases|O the|O behaviour|O stimulation|O evoked|O by|O phenylephrine|O (|O given|O intraventricularly|O )|O in|O rats|O ,|O evaluated|O in|O the|O open|O field|O test|O as|O well|O as|O the|O aggressiveness|B-Disease evoked|O by|O clonidine|O in|O mice|O ,|O both|O these|O effects|O being|O mediated|O by|O an|O alpha1|O -|O adrenergic|O receptor|O .|O
No|O dose|O -|O limiting|O hematologic|O toxicity|B-Disease has|O been|O seen|O .|O
Diabetes|B-Disease mellitus|I-Disease was|O the|O major|O cause|O of|O autonomic|B-Disease neuropathy|I-Disease .|O
Sirolimus|O (|O SRL|O )|O is|O a|O new|O ,|O potent|O immunosuppressive|O agent|O .|O
Therapeutic|O ranges|O for|O antidepressants|O that|O have|O been|O derived|O from|O general|O adult|O population|O studies|O may|O not|O be|O appropriate|O for|O the|O elderly|O .|O
An|O elderly|O patient|O treated|O with|O low|O dose|O Desipramine|O developed|O a|O delirium|B-Disease while|O her|O plasma|O level|O was|O in|O the|O "|O subtherapeutic|O "|O range|O .|O
Therefore|O ,|O PG|O -|O 9|O could|O represent|O a|O potential|O useful|O drug|O able|O to|O improve|O the|O function|O of|O impaired|O cognitive|O processes|O .|O
Recurrent|O acute|O interstitial|B-Disease nephritis|I-Disease induced|O by|O azithromycin|O .|O
Of|O 20|O patients|O evaluable|O for|O toxicity|B-Disease ,|O four|O had|O stage|O III|O and|O 16|O had|O stage|O IV|O disease|O .|O
RESULTS|O :|O Sixty|O percent|O in|O Group|O A|O developed|O postoperative|B-Disease emetic|I-Disease symptoms|I-Disease ,|O headache|B-Disease ,|O or|O both|O ;|O 1|O patient|O in|O Group|O B|O developed|O symptoms|O .|O
Gentamicin|O sulfate|O and|O tobramycin|O sulfate|O continue|O to|O demonstrate|O ototoxicity|B-Disease and|O nephrotoxicity|B-Disease in|O both|O animal|O and|O clinical|O studies|O .|O
For|O the|O first|O few|O days|O after|O ingestion|O ,|O she|O was|O in|O a|O confused|O state|O and|O had|O mild|O to|O moderate|O ataxia|B-Disease and|O giddiness|B-Disease .|O
Serotonergic|O antidepressants|O and|O urinary|B-Disease incontinence|I-Disease .|O
This|O approach|O allowed|O investigating|O the|O efficacy|O of|O alpha|O -|O lipoic|O acid|O in|O preventing|O axonal|B-Disease damage|I-Disease and|O apoptosis|O and|O the|O function|O and|O ultrastructural|O morphology|O of|O mitochondria|O after|O exposure|O to|O toxic|O agents|O and|O alpha|O -|O lipoic|O acid|O .|O
Chromosome|O substitution|O strains|O (|O CSS|O )|O ,|O in|O which|O a|O single|O chromosome|O from|O one|O inbred|O strain|O (|O donor|O )|O has|O been|O transferred|O onto|O a|O second|O strain|O (|O host|O )|O by|O repeated|O backcrossing|O ,|O may|O be|O used|O to|O identify|O quantitative|O trait|O loci|O (|O QTLs|O )|O that|O contribute|O to|O seizure|B-Disease susceptibility|O .|O
Luke|O '|O s|O Hospital|O ,|O Gwardamangia|O ,|O Malta|O .|O
Alpha|O -|O lipoic|O acid|O prevents|O mitochondrial|B-Disease damage|I-Disease and|O neurotoxicity|B-Disease in|O experimental|O chemotherapy|O neuropathy|B-Disease .|O
Her|O acetylcholine|O receptor|O antibody|O level|O was|O markedly|O elevated|O .|O
At|O the|O highest|O effective|O doses|O ,|O PG|O -|O 9|O did|O not|O produce|O any|O collateral|O symptoms|O as|O revealed|O by|O the|O Irwin|O test|O ,|O and|O it|O did|O not|O modify|O spontaneous|O motility|O and|O inspection|O activity|O ,|O as|O revealed|O by|O the|O hole|O -|O board|O test|O .|O
Recurarization|O in|O the|O recovery|O room|O .|O
We|O report|O an|O undiagnosed|O case|O of|O myotonia|B-Disease congenita|I-Disease in|O a|O 24|O -|O year|O -|O old|O previously|O healthy|O primigravida|O ,|O who|O developed|O life|O threatening|O masseter|B-Disease spasm|I-Disease following|O a|O standard|O dose|O of|O intravenous|O suxamethonium|O for|O induction|O of|O anaesthesia|O .|O
Severe|O cardiovascular|B-Disease complications|I-Disease occurred|O in|O eight|O of|O 160|O patients|O treated|O with|O terbutaline|O for|O preterm|B-Disease labor|I-Disease .|O
BACKGROUND|O :|O Incidence|O and|O risk|O factors|O for|O delirium|B-Disease during|O clozapine|O treatment|O require|O further|O clarification|O .|O
The|O results|O suggest|O that|O a|O prolonged|O combination|O of|O more|O than|O 120|O min|O of|O PGE1|O -|O induced|O hypotension|B-Disease and|O moderate|O haemodilution|B-Disease would|O cause|O impairment|B-Disease of|I-Disease hepatic|I-Disease function|I-Disease .|O
In|O vivo|O microdialysis|O demonstrated|O that|O an|O intraperitoneal|O administration|O of|O pilocarpine|O induced|O a|O pronounced|O increment|O of|O hippocampal|O glutamate|O and|O aspartate|O whereas|O no|O significant|O change|O was|O observed|O on|O the|O level|O of|O glycine|O and|O GABA|O .|O
This|O demonstrates|O the|O participation|O of|O the|O renin|O -|O -|O angiotensin|O system|O in|O antagonizing|O the|O combined|O hypotensive|B-Disease effects|O of|O halothane|O and|O SNP|O .|O
Neither|O dose|O of|O pentoxifylline|O significantly|O decreased|O the|O dipyridamole|O -|O induced|O hyperemia|B-Disease ,|O while|O peak|O coronary|O blood|O flow|O was|O significantly|O lower|O after|O theophylline|O (|O p|O less|O than|O 0|O .|O 01|O )|O .|O
In|O conclusion|O mitochondrial|B-Disease toxicity|I-Disease is|O an|O early|O common|O event|O both|O in|O paclitaxel|O and|O cisplatin|O induced|O neurotoxicity|B-Disease .|O
Controlled|O hypotension|B-Disease in|O groups|O A|O and|O C|O was|O induced|O with|O PGE1|O to|O maintain|O mean|O arterial|O blood|O pressure|O at|O 55|O mmHg|O for|O 180|O min|O .|O
Three|O yr|O after|O transplantation|O she|O developed|O renal|B-Disease Fanconi|I-Disease syndrome|I-Disease with|O severe|O metabolic|B-Disease acidosis|I-Disease ,|O hypophosphatemia|B-Disease ,|O glycosuria|B-Disease ,|O and|O aminoaciduria|B-Disease .|O
Heredofamilial|O and|O connective|B-Disease tissue|I-Disease disorders|I-Disease were|O rare|O .|O
It|O may|O be|O concluded|O that|O ,|O like|O other|O tricyclic|O antidepressants|O studied|O previously|O ,|O TRI|O given|O repeatedly|O increases|O the|O responsiveness|O of|O brain|O dopamine|O D2|O and|O D3|O (|O locomotor|O activity|O but|O not|O stereotypy|O )|O as|O well|O as|O alpha1|O -|O adrenergic|O receptors|O to|O their|O agonists|O .|O
Alpha|O -|O lipoic|O acid|O exerts|O neuroprotective|O effects|O against|O chemotherapy|O induced|O neurotoxicity|B-Disease in|O sensory|O neurons|O :|O it|O rescues|O the|O mitochondrial|B-Disease toxicity|I-Disease and|O induces|O the|O expression|O of|O frataxin|O ,|O an|O essential|O mitochondrial|O protein|O with|O anti|O -|O oxidant|O and|O chaperone|O properties|O .|O
Paclitaxel|O /|O cisplatin|O is|O an|O effective|O first|O -|O line|O regimen|O for|O locoregionally|O advanced|O head|B-Disease and|I-Disease neck|I-Disease cancer|I-Disease and|O continued|O study|O is|O warranted|O .|O
Primary|O tumor|B-Disease sites|O were|O oropharynx|O ,|O 10|O patients|O ;|O hypopharynx|O ,|O four|O ;|O larynx|O ,|O two|O ;|O oral|O cavity|O ,|O three|O ;|O unknown|O primary|O ,|O two|O ;|O and|O nasal|O cavity|O and|O parotid|O gland|O ,|O one|O each|O .|O
In|O the|O acute|O experiment|O TRI|O (|O given|O i|O .|O p|O .|O )|O does|O not|O antagonize|O the|O reserpine|O hypothermia|B-Disease in|O mice|O and|O does|O not|O potentiate|O the|O 5|O -|O hydroxytryptophan|O head|O twitches|O in|O rats|O .|O
Repeated|O trimipramine|O induces|O dopamine|O D2|O /|O D3|O and|O alpha1|O -|O adrenergic|O up|O -|O regulation|O .|O
A|O second|O group|O of|O rats|O was|O treated|O identically|O and|O ,|O in|O addition|O ,|O received|O an|O infusion|O of|O saralasin|O (|O a|O competitive|O inhibitor|O of|O angiotensin|O II|O )|O throughout|O the|O experimental|O period|O .|O
The|O diagnostic|O difficulty|O at|O presentation|O is|O highlighted|O .|O
This|O study|O indicates|O that|O with|O stable|O halothane|O anesthesia|O ,|O the|O partial|O recovery|O of|O blood|O pressure|O during|O SNP|O infusion|O and|O the|O post|O -|O SNP|O rebound|O of|O blood|O pressure|O can|O be|O completely|O blocked|O by|O saralasin|O .|O
The|O current|O work|O indicates|O the|O ability|O of|O PG|O -|O 9|O to|O induce|O beneficial|O effects|O on|O cognitive|O processes|O and|O stimulate|O activity|O of|O NGF|O synthesis|O in|O astroglial|O cells|O .|O
OBJECTIVE|O :|O To|O report|O a|O case|O of|O a|O severe|O interaction|O between|O simvastatin|O ,|O amiodarone|O ,|O and|O atazanavir|O resulting|O in|O rhabdomyolysis|B-Disease and|O acute|B-Disease renal|I-Disease failure|I-Disease .|O
Alpha|O -|O lipoic|O acid|O protects|O sensory|O neurons|O through|O its|O anti|O -|O oxidant|O and|O mitochondrial|O regulatory|O functions|O ,|O possibly|O inducing|O the|O expression|O of|O frataxin|O .|O
A|O question|O arises|O whether|O the|O reuptake|O inhibition|O is|O of|O any|O importance|O to|O the|O adaptive|O changes|O induced|O by|O repeated|O antidepressants|O ,|O suggested|O to|O be|O responsible|O for|O the|O antidepressant|O activity|O .|O
Nitro|O -|O L|O -|O arginine|O methyl|O ester|O :|O a|O potential|O protector|O against|O gentamicin|O ototoxicity|B-Disease .|O
Granulocyte|O nadir|O was|O on|O day|O 14|O (|O range|O ,|O 4|O -|O 22|O )|O .|O
Five|O of|O 33|O (|O 15|O %|O )|O of|O the|O tobramycin|O -|O treated|O patients|O and|O 16|O of|O 29|O (|O 55|O .|O 2|O %|O )|O of|O the|O gentamicin|O -|O treated|O patients|O had|O renal|B-Disease failure|I-Disease .|O
Total|O cumulative|O doses|O were|O 36|O or|O 60|O g|O /|O m2|O of|O ifosfamide|O (|O six|O or|O 10|O cycles|O of|O ifosfamide|O ,|O vincristine|O ,|O and|O dactinomycin|O [|O IVA|O ]|O )|O .|O
Electron|O microscopical|O immunohistochemistry|O revealed|O positive|O reaction|O products|O noted|O on|O the|O secretory|O granules|O ,|O Golgi|O cisternae|O ,|O and|O endoplasmic|O reticulum|O of|O the|O untreated|O rat|O prolactinoma|B-Disease cells|O .|O
Her|O vocal|O change|O and|O weakness|O began|O to|O improve|O spontaneously|O about|O 3|O weeks|O after|O transfer|O .|O
These|O children|O were|O older|O and|O were|O more|O likely|O to|O have|O undergone|O recent|O bowel|O surgery|O than|O are|O other|O children|O with|O this|O condition|O .|O
In|O a|O patient|O with|O WPW|B-Disease syndrome|I-Disease and|O idiopathic|B-Disease dilated|I-Disease cardiomyopathy|I-Disease ,|O intractable|O atrioventricular|B-Disease reentrant|I-Disease tachycardia|I-Disease (|O AVRT|B-Disease )|O was|O iatrogenically|O induced|O .|O
Thirteen|O biopsies|O were|O performed|O from|O stable|O functioning|O renal|O allografts|O with|O informed|O consent|O (|O nonepisode|O biopsy|O )|O and|O the|O other|O 13|O were|O from|O dysfunctional|O renal|O allografts|O with|O a|O clinical|O indication|O for|O biopsy|O (|O episode|O biopsy|O )|O .|O
Biopsies|O performed|O in|O five|O patients|O revealed|O new|O pathological|O changes|O :|O One|O membranoproliferative|B-Disease glomerulopathy|I-Disease and|O interstitial|B-Disease nephritis|I-Disease .|O
Severe|O distress|O was|O noted|O in|O the|O recovery|O phase|O in|O two|O patients|O .|O
Two|O patients|O with|O type|B-Disease II|I-Disease diabetes|I-Disease mellitus|I-Disease developed|O an|O acute|B-Disease hepatitis|I-Disease -|I-Disease like|I-Disease syndrome|I-Disease soon|O after|O initiation|O of|O glyburide|O therapy|O .|O
Thus|O ,|O gentamicin|O was|O associated|O with|O renal|B-Disease failure|I-Disease more|O than|O three|O times|O as|O often|O as|O was|O tobramycin|O .|O
CONCLUSION|O :|O This|O rat|O study|O demonstrated|O a|O synergistic|O nephrotoxic|B-Disease effect|O of|O CsA|O plus|O SRL|O ,|O whereas|O FK506|O plus|O SRL|O was|O better|O tolerated|O .|O
Use|O of|O chromosome|O substitution|O strains|O to|O identify|O seizure|B-Disease susceptibility|O loci|O in|O mice|O .|O
Histological|O studies|O demonstrated|O that|O the|O rats|O developed|O an|O infarct|B-Disease 18|O h|O after|O isoproterenol|O administration|O .|O
Delirium|B-Disease was|O inconsistently|O recognized|O clinically|O in|O milder|O cases|O and|O was|O associated|O with|O increased|O length|O -|O of|O -|O stay|O and|O higher|O costs|O ,|O and|O inferior|O clinical|O outcome|O .|O
The|O FK506|O plus|O SRL|O combination|O showed|O only|O a|O marginally|O higher|O degree|O of|O fibrosis|B-Disease as|O compared|O with|O controls|O (|O P|O =|O 0|O .|O 05|O )|O .|O
Proteinuria|B-Disease after|O conversion|O to|O sirolimus|O in|O renal|O transplant|O recipients|O .|O
Among|O these|O behavioral|O effects|O are|O decreases|O in|O food|O intake|O and|O decreases|O in|O amphetamine|O -|O induced|O locomotor|O activity|O .|O
Desipramine|O -|O induced|O delirium|B-Disease at|O "|O subtherapeutic|O "|O concentrations|O :|O a|O case|O report|O .|O
VPU|O was|O more|O potent|O than|O VPA|O ,|O exhibiting|O the|O median|O effective|O dose|O (|O ED|O (|O 50|O )|O )|O of|O 49|O mg|O /|O kg|O in|O protecting|O rats|O against|O pilocarpine|O -|O induced|O seizure|B-Disease whereas|O the|O corresponding|O value|O for|O VPA|O was|O 322|O mg|O /|O kg|O .|O
QTLs|O for|O susceptibility|O to|O pilocarpine|O -|O induced|O seizures|B-Disease ,|O a|O model|O of|O temporal|B-Disease lobe|I-Disease epilepsy|I-Disease ,|O have|O not|O been|O reported|O ,|O and|O CSS|O have|O not|O previously|O been|O used|O to|O localize|O seizure|B-Disease susceptibility|O genes|O .|O
The|O anatomical|O and|O aetiological|O diagnoses|O of|O peripheral|B-Disease nerve|I-Disease disease|I-Disease excluding|O its|O primary|O benign|O and|O malignant|O disorders|O ,|O as|O seen|O in|O 358|O Nigerians|O are|O presented|O .|O
Ages|O ranged|O from|O 4|O months|O to|O 17|O years|O ;|O 58|O patients|O were|O males|O and|O 42|O females|O .|O
The|O aim|O of|O this|O study|O was|O to|O investigate|O whether|O autophagy|O was|O involved|O in|O the|O progression|O of|O heart|B-Disease failure|I-Disease induced|O by|O adriamycin|O ,|O so|O that|O we|O can|O develop|O a|O novel|O treatment|O strategy|O for|O heart|B-Disease failure|I-Disease .|O
Pretreatment|O with|O either|O VPU|O (|O 50|O and|O 100|O mg|O /|O kg|O )|O or|O VPA|O (|O 300|O and|O 600|O mg|O /|O kg|O )|O completely|O abolished|O pilocarpine|O -|O evoked|O increases|O in|O extracellular|O glutamate|O and|O aspartate|O .|O
Latencies|O to|O stages|O were|O also|O significantly|O shorter|O for|O CSS10|O and|O CSS18|O mice|O .|O
Bromocriptine|O -|O induced|O hypotension|B-Disease was|O unaffected|O by|O isoproterenol|O pretreatment|O ,|O while|O tachycardia|B-Disease was|O reversed|O to|O significant|O bradycardia|B-Disease ,|O an|O effect|O that|O was|O partly|O reduced|O by|O i|O .|O v|O .|O domperidone|O (|O 0|O .|O 5|O mg|O /|O kg|O )|O .|O
TRI|O given|O repeatedly|O to|O rats|O increases|O the|O locomotor|O hyperactivity|B-Disease induced|O by|O d|O -|O amphetamine|O ,|O quinpirole|O and|O (|O +|O )|O -|O 7|O -|O hydroxy|O -|O dipropyloaminotetralin|O (|O dopamine|O D2|O and|O D3|O effects|O )|O .|O
Laboratory|O evaluation|O revealed|O 66|O ,|O 680|O U|O /|O L|O creatine|O kinase|O ,|O 93|O mg|O /|O dL|O blood|O urea|O nitrogen|O ,|O 4|O .|O 6|O mg|O /|O dL|O creatinine|O ,|O 1579|O U|O /|O L|O aspartate|O aminotransferase|O ,|O and|O 738|O U|O /|O L|O alanine|O aminotransferase|O .|O
Pharmacokinetic|O analyses|O in|O 21|O patients|O revealed|O Pirarubicin|O plasma|O T|O 1|O /|O 2|O alpha|O (|O +|O /|O -|O SE|O )|O of|O 2|O .|O 5|O +|O /|O -|O 0|O .|O 85|O minutes|O ,|O T|O beta|O 1|O /|O 2|O of|O 25|O .|O 6|O +|O /|O -|O 6|O .|O 5|O minutes|O ,|O and|O T|O 1|O /|O 2|O gamma|O of|O 23|O .|O 6|O +|O /|O -|O 7|O .|O 6|O hours|O .|O
Nearly|O 3|O .|O 2|O million|O people|O in|O this|O country|O receive|O aminoglycoside|O antibiotics|O annually|O .|O
In|O group|O C|O ,|O AKBR|O showed|O a|O significant|O decrease|O at|O 120|O min|O (|O -|O 40|O %|O )|O and|O at|O 180|O min|O (|O -|O 49|O %|O )|O after|O the|O start|O of|O hypotension|B-Disease and|O at|O 60|O min|O (|O -|O 32|O %|O )|O after|O recovery|O of|O normotension|O ,|O and|O SGOT|O ,|O SGPT|O ,|O LDH|O and|O total|O bilirubin|O showed|O significant|O increases|O after|O operation|O .|O
These|O results|O show|O that|O 15|O -|O day|O isoproterenol|O pretreatment|O not|O only|O abolished|O but|O reversed|O bromocriptine|O -|O induced|O tachycardia|B-Disease to|O bradycardia|B-Disease ,|O an|O effect|O that|O is|O mainly|O related|O to|O further|O cardiac|O beta|O -|O adrenoceptor|O desensitization|O rather|O than|O to|O impairment|O of|O autonomic|O regulation|O of|O the|O heart|O .|O
Highest|O stage|O reached|O and|O latency|O to|O each|O stage|O were|O recorded|O for|O all|O mice|O .|O
The|O CSS|O for|O Chromosomes|O 10|O and|O 18|O progressed|O to|O the|O most|O severe|O stages|O ,|O diverging|O dramatically|O from|O the|O B6|O phenotype|O .|O
A|O nerve|O conduction|O study|O was|O consistent|O with|O severe|O sensorimotor|O axonal|O polyneuropathy|B-Disease .|O
Contact|O with|O the|O skin|O can|O result|O in|O percutaneous|O absorption|O of|O the|O substance|O that|O inhibits|O aldehyde|O dehydrogenase|O and|O can|O induce|O acetaldehyde|O syndrome|O in|O case|O of|O alcohol|O use|O .|O
RESULTS|O :|O The|O main|O pathologic|O diagnoses|O (|O some|O overlap|O )|O were|O acute|O rejection|O (|O AR|O ;|O n|O =|O 4|O )|O ,|O chronic|O rejection|O (|O CR|O ;|O n|O =|O 5|O )|O ,|O AR|O +|O CR|O (|O n|O =|O 4|O )|O ,|O recurrent|O IgA|B-Disease nephropathy|I-Disease (|O n|O =|O 5|O )|O ,|O normal|O findings|O (|O n|O =|O 2|O )|O ,|O minimal|O -|O type|O chronic|O FK506|O nephropathy|B-Disease (|O n|O =|O 9|O )|O ,|O and|O mild|O -|O type|O FK506|O nephropathy|B-Disease (|O n|O =|O 11|O )|O .|O
Acute|O peripheral|B-Disease neuropathy|I-Disease caused|O by|O a|O disulfiram|O overdose|B-Disease is|O very|O rare|O and|O there|O is|O no|O report|O of|O it|O leading|O to|O vocal|B-Disease fold|I-Disease palsy|I-Disease .|O
Fanconi|B-Disease syndrome|I-Disease ,|O as|O well|O as|O myopathy|B-Disease ,|O is|O well|O recognized|O in|O patients|O with|O mitochondrial|B-Disease disorders|I-Disease and|O caused|O by|O depletion|O of|O mtDNA|O .|O
Kidney|O function|O and|O morphology|O after|O short|O -|O term|O combination|O therapy|O with|O cyclosporine|O A|O ,|O tacrolimus|O and|O sirolimus|O in|O the|O rat|O .|O
Intravenous|O administration|O of|O a|O single|O 50|O -|O mg|O bolus|O of|O lidocaine|O in|O a|O 67|O -|O year|O -|O old|O man|O resulted|O in|O profound|O depression|B-Disease of|O the|O activity|O of|O the|O sinoatrial|O and|O atrioventricular|O nodal|O pacemakers|O .|O
Pentoxifylline|O (|O Trental|O )|O does|O not|O inhibit|O dipyridamole|O -|O induced|O coronary|O hyperemia|B-Disease :|O implications|O for|O dipyridamole|O -|O thallium|O -|O 201|O myocardial|O imaging|O .|O
The|O dose|O -|O limiting|O toxic|O effect|O was|O transient|O noncumulative|O granulocytopenia|B-Disease .|O
An|O increase|B-Disease in|I-Disease blood|I-Disease pressure|I-Disease ,|O accompanied|O by|O atrial|B-Disease fibrillation|I-Disease ,|O agitation|B-Disease ,|O incomprehensible|B-Disease shouts|I-Disease and|O loss|B-Disease of|I-Disease consciousness|I-Disease ,|O was|O observed|O in|O an|O elderly|O ,|O ASA|O classification|O group|O II|O ,|O cardiovascularly|O medicated|O male|O ,|O 12|O min|O after|O performance|O of|O axillary|O block|O with|O mepivacaine|O 850|O mg|O containing|O adrenaline|O 0|O .|O 225|O mg|O ,|O for|O correction|O of|O Dupuytren|B-Disease '|I-Disease s|I-Disease contracture|I-Disease .|O
Fatal|O myeloencephalopathy|B-Disease due|O to|O accidental|O intrathecal|O vincristin|O administration|O :|O a|O report|O of|O two|O cases|O .|O
Long|O -|O term|O follow|O -|O up|O of|O ifosfamide|O renal|B-Disease toxicity|I-Disease in|O children|O treated|O for|O malignant|B-Disease mesenchymal|I-Disease tumors|I-Disease :|O an|O International|O Society|O of|O Pediatric|O Oncology|O report|O .|O
CONCLUSIONS|O :|O Delirium|B-Disease was|O found|O in|O 10|O %|O of|O clozapine|O -|O treated|O inpatients|O ,|O particularly|O in|O older|O patients|O exposed|O to|O other|O central|O anticholinergics|O .|O
Therefore|O ,|O conversion|O should|O be|O considered|O for|O patients|O who|O have|O not|O developed|O advanced|O CAN|B-Disease and|O proteinuria|B-Disease .|O
We|O determined|O the|O BChE|O activity|O and|O the|O BCHE|O genotype|O using|O molecular|O genetic|O methods|O ,|O the|O duration|O of|O apnea|B-Disease ,|O time|O to|O sufficient|O spontaneous|O ventilation|O and|O whether|O neuromuscular|O monitoring|O was|O used|O .|O
The|O serum|O creatinine|O levels|O of|O patients|O in|O the|O mild|O -|O type|O chronic|O FK506|O nephropathy|B-Disease group|O ,|O which|O included|O 7|O episode|O biopsies|O ,|O were|O statistically|O higher|O than|O those|O in|O the|O minimum|O -|O type|O chronic|O FK506|O -|O nephropathy|B-Disease group|O (|O P|O <|O 0|O .|O 001|O )|O .|O
The|O aim|O of|O the|O study|O was|O to|O assess|O the|O clinical|O significance|O of|O genetic|O variants|O in|O butyrylcholinesterase|O gene|O (|O BCHE|O )|O in|O patients|O with|O a|O suspected|O prolonged|O duration|O of|O action|O of|O succinylcholine|O after|O ECT|O .|O
Trimipramine|O (|O TRI|O )|O ,|O which|O shows|O a|O clinical|O antidepressant|O activity|O ,|O is|O chemically|O related|O to|O imipramine|O but|O does|O not|O inhibit|O the|O reuptake|O of|O noradrenaline|O and|O 5|O -|O hydroxytryptamine|O ,|O nor|O does|O it|O induce|O beta|O -|O adrenergic|O down|O -|O regulation|O .|O
ROIs|O drawn|O over|O the|O gamma|O camera|O images|O showed|O a|O ratio|O of|O 4|O .|O 4|O .|O
This|O low|O percentage|O (|O 5|O %|O )|O of|O TDFS|O must|O be|O evaluated|O with|O respect|O to|O the|O efficacy|O of|O ifosfamide|O in|O the|O treatment|O of|O mesenchymal|B-Disease tumors|I-Disease in|O children|O .|O
While|O she|O was|O weak|O ,|O 2|O -|O Hz|O repetitive|O stimulation|O revealed|O a|O decrement|O without|O significant|O facilitation|O at|O rapid|O rates|O or|O after|O exercise|O ,|O suggesting|O postsynaptic|B-Disease neuromuscular|I-Disease blockade|I-Disease .|O
Eighty|O -|O nine|O new|O referral|O hypertensive|B-Disease out|O -|O patients|O and|O 46|O new|O referral|O non|O -|O hypertensive|B-Disease chronically|O physically|O ill|O out|O -|O patients|O completed|O a|O mood|O rating|O scale|O at|O regular|O intervals|O for|O one|O year|O .|O
The|O patient|O recovered|O spontaneously|O in|O 3|O hours|O under|O surveillance|O in|O the|O hospital|O .|O
The|O possibility|O of|O de|O novo|O glomerular|O pathology|O under|O SRL|O treatment|O requires|O further|O investigation|O by|O renal|O biopsy|O .|O
Baseline|O circumflex|O coronary|O blood|O flows|O did|O not|O differ|O significantly|O among|O treatment|O groups|O .|O
Ketoconazole|O -|O induced|O neurologic|B-Disease sequelae|I-Disease .|O
A|O phase|O I|O /|O II|O study|O of|O paclitaxel|O plus|O cisplatin|O as|O first|O -|O line|O therapy|O for|O head|B-Disease and|I-Disease neck|I-Disease cancers|I-Disease :|O preliminary|O results|O .|O
At|O the|O time|O of|O this|O writing|O ,|O dose|O level|O 4|O (|O 260|O ,|O 270|O ,|O and|O 280|O mg|O /|O m2|O )|O is|O being|O evaluated|O ;|O three|O patients|O from|O this|O level|O are|O evaluable|O .|O
Seven|O patients|O suffering|O from|O Parkinson|B-Disease '|I-Disease s|I-Disease disease|I-Disease (|O PD|B-Disease )|O with|O severely|O disabling|O dyskinesia|B-Disease received|O low|O -|O dose|O propranolol|O as|O an|O adjunct|O to|O the|O currently|O used|O medical|O treatment|O .|O
A|O new|O infarct|B-Disease -|O avid|O radiopharmaceutical|O based|O on|O glucaric|O acid|O was|O prepared|O in|O the|O hospital|O radiopharmacy|O of|O the|O INCMNSZ|O .|O 99mTc|O -|O glucarate|O was|O easy|O to|O prepare|O ,|O stable|O for|O 96|O h|O and|O was|O used|O to|O study|O its|O biodistribution|O in|O rats|O with|O isoproterenol|O -|O induced|O acute|O myocardial|B-Disease infarction|I-Disease .|O
RESULTS|O :|O CsA|O ,|O FK506|O and|O SRL|O all|O significantly|O decreased|O the|O GFR|O .|O
We|O used|O an|O in|O vitro|O model|O of|O chemotherapy|O induced|O peripheral|B-Disease neuropathy|I-Disease that|O closely|O mimic|O the|O in|O vivo|O condition|O by|O exposing|O primary|O cultures|O of|O dorsal|O root|O ganglion|O (|O DRG|O )|O sensory|O neurons|O to|O paclitaxel|O and|O cisplatin|O ,|O two|O widely|O used|O and|O highly|O effective|O chemotherapeutic|O drugs|O .|O
This|O approach|O provides|O a|O framework|O for|O identifying|O potentially|O novel|O homologous|O candidate|O genes|O for|O human|O temporal|B-Disease lobe|I-Disease epilepsy|I-Disease .|O
METHODS|O :|O a|O total|O of|O 13|O patients|O were|O referred|O to|O the|O Danish|O Cholinesterase|O Research|O Unit|O after|O ECT|O during|O 38|O months|O .|O
